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„Das Schönste, was wir erleben können, ist das Geheimnisvolle.“ 
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1. Summary 
In my thesis I focused on novel aspects of alpha-1-antitrypsin (AAT or serpina1) and its close 
relative, serpina2 (alpha-1-antitrypsin related protein), a gene in physical proximity to the 
AAT gene.  
Put in a nutshell, in the first described project we found that serpina2 is not a pseudogene as 
previously suggested. In a recent publication on serpina2, a broad tissue distribution was 
reported and a protease inhibiting function for serpina2 was discussed, but specific analytical 
tools were not available at that time. The goal of this study was to develop appropriate tools 
and procedures to clarify the role of serpina2 as a potential modifier of inflammatory 
diseases. We used cDNA of many human tissues in qPCR experiments and found serpina2 
mRNA exclusively expressed in the epididymis. In addition, we explored recombinant 
expression of serpina2 and established rat monoclonal antibodies, which were used for 
immune histology, Western blots and a sandwich ELISA. To search for potential target 
proteases we used fluorescence resonance energy transfer (FRET) substrates derived from 
the reactive center loop of serpina2 in activity assays. After transfection of HEK 293 cells, the 
vast majority of the protein remained inside in association with the host cells, while only small 
amounts of the normally secreted protein were found in the culture supernatant, suggesting 
that poor folding and aggregation propensity of serpina2 may contribute to cellular stress and 
tissue inflammation, like a well-known coding variant of serpina1. With our monoclonal 
antibodies we were able to detect serpina2 in epididymal tissue lysates of men. A serpina1 
chimera, carrying the reactive center loop of serpina2, was cleaved by chymotrypsin 
suggesting chymotrypsin-like proteases are putative targets of serpina2. In conclusion, 
serpina2 is not a pseudogene; it is an epididymis specific potential inhibitor of chymotrypsin-
like proteases and may improve sperm maturation, male fertility and reproductive success.  
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In the second project, we characterized two common coding variants of AAT by comparing 
them in a hydrogen/deuterium exchange experiment combined with mass spectrometry. We 
revealed that a common single-amino acid variation is not functionally neutral, but affects the 
overall structural flexibility of the variants and their ability to fulfill their role as protease 
inhibitor. 
In the third project we describe a new method to improve storage of donor lungs by adding 
AAT to the perfusion and storage solution, which could allow extended storage and better 
preservation before implantation. Primary graft dysfunction and vascular damage of donor 
lungs immediately after blood reperfusion in the recipient increases with prolonged 
preservation times. Hence, cold ischemic storage for only six hours is generally accepted, 
after lungs are cooled down and conserved in an extracellular, colloid-based electrolyte 
solution. Natural AAT, a highly abundant human plasma proteinase inhibitor with additional 
putative functions in vivo, has been approved as a therapeutic in AAT deficiency patients. 
Using a realistic clinically oriented murine model of lung transplantation and adding AAT with 
a functional reactive center loop to a widely used preservation solution (Perfadex), we found 
that ischemic storage times of lung grafts at 4 degrees can be extended to 18 h with 
improved graft function after reperfusion in recipient mice. Double knockout recipients that 
lack elastase-like activities in neutrophils were also protected from early reperfusion injury, 
but not those lung grafts that were perfused with a reactive center mutant of AAT devoid of 
elastase-inhibiting activity. We conclude that the proteinase 3 and elastase inhibiting 
classical function of tissue AAT reduces the early reperfusion-related injury of transplanted 
lungs after extended ischemic storage, which makes it a promising strategy for improvement 
of organ preservation. 
2 Introduction 
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2. Introduction 
 The superfamily of Serpins 2.1
The primary function of serpins is the inhibition of serine proteases. In fact, the term serpin is 
an acronym for serine protease inhibitor and was coined by Robin Carrell and Jim Travis in 
19851. The term is somewhat misleading since not all serpins are inhibitors of serine 
proteases, some also inhibit cysteine proteases (cross-class inhibition) and several members 
of the family carry out other important biological functions such as molecular chaperoning 
(HSP47)2, hormone carriage (thyroxine- or cortisol-binding-protein3) or presumably storage 
(ovalbumin in egg-white). Despite their different functions, all members of the superfamily are 
called serpins because of their shared structure and common evolutionary origin4. Serpins 
are present in all kingdoms of life5-7. With approximately 1,500 members they represent the 
largest family of protease inhibitors8. In the human genome 35 putatively functional serpins 
(including at least 29 with inhibitory function) plus five putative pseudogenes were 
identified9,10. The superfamily is divided into clades and numbers based upon a phylogenetic 
analysis. For instance, serpina1 belongs to clade A and one is the number of the protein 
within the clade. 
The serpin secondary structure is highly conserved, they consist of 8 or more alpha helices, 
three ß-sheets (A, B and C) and a reactive center loop (RCL), which serves as bait for target 
proteases11. The 20 – 24 amino acid long RCL is flexible and exposed, and therefore easily 
accessible for proteases12. Most serpins are secreted and circulate in their native metastable 
state with an intact RCL. They inhibit their target proteases in a very unique way by using an 
unusual conformational change that disrupts the protease structure depriving it of its activity. 
The major conformational change converts the serpin from a stressed state (high energy) to 
a relaxed state (low energy), which is also called the S to R transition. During this transition 
the RCL is inserted into ß-sheet A leading to significantly increased thermal stability  
(Figure 2.1)10,13.  
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Figure 2.1 Structure and inhibitory mechanism of serpins. (a) Native serpina1 (alpha1-
antitrypsin) based on PDB IQLP), red: A-sheet, green: B-sheet, yellow: C-sheet, blue: 
helices, magenta: RCL (reactive center loop) and dashed line marking the path of the RCL 
insertion into ß-sheet A. (b) Michaelis or docking complex between serpina1 and trypsin 
(based on PDB IOPH). After docking with an active protease two pathways are possible:  
(c) The irreversible serpin-enzyme complex (based on PDB IEZX). S to R transition took 
place, the serpin rapidly transforms to the energetically favorable relaxed state by inserting 
the reactive center loop into ß-sheet A. (d) Cleaved structure of serpina1 (based on PDB 
7API). (Modified from Law et al.8)  
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The serpin mechanism of protease inhibition has been studied extensively by structural 
biologists and biochemists (reviewed in4,11,12). Initially, a non-covalent protease-inhibitor 
Michaelis complex is formed. Subsequently, the peptide bond in the serpin’s RCL is cleaved 
through a nucleophilic attack by the catalytic triad (Asp, His, Ser/Cys) of the protease. The 
Schechter-Berger nomenclature for protease substrate interaction is used to number the 
RCL residues (P-residues) and the respective protease subsites close to the active site (S-
regions). The scissile bond (cleavage site) is located between P1 and P1’14. The S1 pocket of 
the protease interacts with the specificity-determining P1 residue of the inhibitor15-17. P17 – 
P1 are used for numbering the N-terminal side of the scissile bond and P1’ – P6’ for the C-
terminal side14. The second step of the interaction is the formation of an ester bond between 
the enzyme and the substrate or the pseudo-substrate. For usual substrates the ester bond 
is hydrolyzed and the protease is set free. When the substrate happens to be a serpin 
(pseudo-substrate), the RCL inserts into ß-sheet A resulting in a relocation of the protease 
from one end to the distal end. Thereby the acyl-enzyme intermediate becomes kinetically 
trapped leading to an irreversible inhibition of the protease. This process leads to a 
destruction of the oxyanion hole by distorting the active center of the protease11,12 Serpins 
are not only classed as irreversible inhibitors, but also as suicide inhibitors since they can 
only inactivate a single protease molecule and are no longer active after their dissociation 
from the protease. Their inhibitory activity cannot be recovered by dissociation from the 
protease.  
  
2 Introduction 
6 
 
 Alpha-1-antitrypsin (AAT or serpina1)  2.2
One of the best studied serpins is alpha-1-antitrypsin. It is one of the most abundant proteins 
in human blood (20 – 53 µM) making up 10 % of all plasma proteins18-20. It is expressed 
primarily in hepatocytes in the liver and then distributed via the blood throughout the body. Its 
major physiological role is the inhibition of excessive proteases. When the protease inhibitor 
was first recognized as an inhibitor of trypsin, it was called alpha-1-antitrypsin, but further 
studies revealed that it is the most efficient inhibitor of neutrophil elastase21. Very high levels 
of alpha-1-antitrypsin are required to inhibit proteases effectively. In an acute phase 
response normal plasma levels are dramatically increased by enhanced de novo synthesis in 
the liver. These higher systemic levels protect connective tissue fibers more efficiently 
against elastase released by activated neutrophil granulocytes. 
 Alpha-1-antitrypsin deficiency 2.3
Tight regulation of proteases is very important and in a healthy system the inhibitor 
concentration is much higher than the protease concentration. Proteases are not properly 
inhibited when there is an imbalance between inhibitors and proteases as it happens in 
individuals with lower levels of alpha-1-antitrypsin, who are predisposed towards the 
development of pulmonary emphysema. Alpha-1-antitrypsin deficiency is an inherited 
disease. Two codominant alleles determine the concentration of alpha-1-antitrypsin in the 
blood stream. The most common and well characterized mutation in individuals with 
European ancestry is the so called Z variant (Glu342→Lys342)22,23. Individuals homozygous for 
the Z-allele show only 10 - 15% of normal levels and develop emphysema in 80 - 90% of 
cases (according to Orphanet, a European rare disease database). Additionally, the Z-type of 
alpha-1-antitrypsin accumulates in hepatocytes due to misfolding and the mutation 
sometimes results in liver cirrhosis24. 
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Patients are treated intravenously with purified human alpha-1-antitrypsin to raise the level in 
the blood and lungs (augmentation therapy). The ultimate treatment of end stage lung and 
liver disease is the transplantation of these organs. 
 Objectives of this dissertation 2.4
Alpha-1-antitrypsin has been studied extensively, however, very little is known about its 
direct neighbor gene serpina2, which was originally thought to be a pseudogene. In recent 
studies serpina2 expression was proposed again and in this thesis we evaluated the new 
data on serpina2 with the goal to study the protein and its function as putative protease 
inhibitor.  
The second part of this dissertation characterizes common coding variants of alpha-1-
antitrypsin by comparing different proteins in a hydrogen/deuterium exchange experiment 
combined with mass spectrometry to reveal their different functional properties. 
In the third and last chapter we describe a new therapeutic approach to use alpha-1-
antitryspin in lung transplantation. We evaluated whether storage and transplantability of 
donor lungs can be improved by adding the protease inhibitor to the storage solution during 
cold ischemia in a murine orthotopic lung transplantation model. 
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3. Materials and methods 
 Materials 3.1
 Chemicals and Consumables 3.1.1
Chemicals were purchased from the companies BD Biosciences (Franklin Lakes, NJ, USA), 
Bio-Rad Laboratories (Hercules, CA, USA), Biozym (Hessisch Oldendorf, Germany), Life 
Technologies (Carlsbad, CA, USA), Merck (Darmstadt, Germany), PAA Laboratories GmbH 
(Pasching, Austria), GE Healthcare (Little Chalfont, Buckinghamshire, UK), Qiagen (Hilden, 
Deutschland), Roth (Karlsruhe, Germany), and Sigma-Aldrich (St Louis, MO, USA), unless 
mentioned otherwise. Restriction enzymes and T4 DNA ligase were purchased from New 
England Biolabs (Ipswich, MA, USA) and Thermo Fisher Scientific (Waltham, MA, USA). 
Consumables such as pipette tips, centrifuge tubes, reaction tubes, and microwell plates 
were procured from Biozym (Hessisch Oldendorf, Germany), Eppendorf (Hamburg, 
Germany), BD Biosciences and Nunc/Thermo Fisher Scientific (Waltham, MA, USA). Cell 
culture flasks and dishes were obtained from Corning (Corning, NY, USA) and BD 
Biosciences. 
 Laboratory equipment 3.1.2
Autoklave  Varioklav, H+P Labortechnik, Oberschleissheim, Germany 
Balances  PM 4800 Delta Range, Mettler-Toledo, Columbus, OH, USA 
2001 MP2, Sartorius, Göttingen, Deutschland 
Centrifuges    5417R, Eppendorf 
5417C, Eppendorf 
Rotanta 460R, Hettich, Tuttlingen, Germany 
Rotanta/R, Hettich 
Film developer   X-Omat M35, Kodak 
FPLC     ÄKTAprimeTM, Amersham-Pharmacia 
Gel electrophoresis 
chambers/ power supplies Bio-Rad, Amersham-Pharmacia, MPI workshop 
Incubation shaker  HT Multitron, Infors, Bottmingen, Switzerland 
Incubator  BBD6220, Heraeus, Thermo Scientific, Waltham, MA, USA 
Incubator    Jouan, Germany 
Icemachine    Ziegra, Isernhagen, Germany 
Laminar flow    LaminAir HB 2472S, Heraeus, Hanau, Germany 
Magnetic stirrer   MR3003, Heidolph, Kelheim, Germany 
KMO2 basic, IKA, Staufen, Germany 
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Microplate reader   FLUOStar Optima, BMG Labtech, Offenburg, Germany 
Microscope   Leica DM IL, Leica Microsystems, Wetzlar, Germany 
pH-meter    Inolab pH Level 1, WTW, Weilheim, Germany 
PCR cycler    T3 Thermocycler, Biometra, Göttingen, Germany 
Semidry blotter  Biometra, Göttingen, Germany 
Shakers    130 basic, IKA KS 
260 basic, IKA KS 
Spectrophotometer   ND-1000, peqlab, Erlangen, Germany 
Biophotometer, Eppendorf 
Thermoblock    Thermomixer 5436, Eppendorf 
Ultrasonic bath   Sonorex digital 10P, Bandelin, Berlin, Germany 
Water bath incubator  MA6, Lauda, Lauda-Königshofen, Germany 
Water preparation   Milli Q Advantage, Millipore, Billerica, MA, USA 
 
 Oligonucleotides 3.1.3
Oligonucleotides were synthesized by Eurofins Genomics (Ebersberg, Germany).  
Oligonucleotide Sequence 
Serpina2 qPCR  
DJ3701_SerpA2for 5’-TGGAGAAAAGAACTGGAAGA-3’ 
DJ3702_SerpA2rev 5’-ATGTCAAATCTACCCAGGTG-3’ 
Serpina2 genotyping  
DJ3754_SA2_ex2f3 5’-GCCTCTGTCTTGCAGGAGAAT-3’ 
DJ3751_SA2_r3 5’-TCGGTGTCCCTGAAGTTGAT-3’ 
Cloning 
pET24c_serpina2_His 
 
DJ3706_serpa2_f 5’-CGGGGATCCATGCAGAAGATCTCCTATAACGT-3’ 
DJ3707_serpa2_r 5’-GTGGTGCTCGAGTTTTTGGGTGGGATTCACCAC-3’ 
Cloning AAT
mt
  
DJ3708 5’-TCGAGGACCCTGACTCATCG-3’ 
DJ3709 5’-ATCGATGAGTCAGGGTCC-3’ 
Cloning 
pETSUMOSerpina2 
 
pETSUMOSerpinA2_F 5’-TGGTGGACAGAAGATCTCCTATAACGTCACCG-3’ 
pETSUMOSerpinA2_R 5’-GAGTACTTTATTTTTGGGTGGGATTC-3’ 
 
Cloning PQEserpina2 
 
F1_PQEserpinA2_F 5’-tccaaGGACAGAAGATCTCCTATAACGTCAC-3’ 
F1_PQEserpinA2_R 5’-GCTtcattaTTTTTGGGTGGGATTCACC-3’ 
 Plasmids 3.1.4
Plasmid Construct  Origin  
pTT5 - 
NRC Biotechnology Research Institute 
(Ottawa, Ontario, Canada) 
 
pTT5-hAAT SigIgκ-AAT-H6 Therese Dau, AG Jenne  
pTT5-hAAT M1(V213)  Therese Dau, AG Jenne  
pTT5-hAAT M1 (A213)  Therese Dau, AG Jenne  
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Pet24-c(+) - 69751, Novagen  
Pet28_His_SUMO - Huntington lab, Cambridge  
Vector maps can be found in the Appendix (9). 
 E.coli bacterial strains 3.1.5
Strain Genotype  Source  
DH5α 
F– Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 
hsdR17 (rK–, mK+) phoA supE44 λ– thi-1 gyrA96 relA1 
18265017, 
Thermo Fisher 
Scientific 
 
BL21 
fhuA2 [lon] ompT gal (λ DE3) [dcm] ∆hsdS 
λ DE3 = λ sBamHIo ∆EcoRI-B int::(lacI::PlacUV5::T7 gene1) 
i21 ∆nin5 
C2527I, NEB  
SHuffle® Express 
fhuA2 [lon] ompT ahpC gal λatt::pNEB3-r1-cDsbC (SpecR, 
lacI
q) ΔtrxB sulA11 R(mcr-73::miniTn10--TetS)2 [dcm] R(zgb-
210::Tn10 --Tet
S
) endA1 Δgor ∆(mcrC-mrr)114::IS10 
C3028J, NEB  
Rosetta™ 
2(DE3)pLysS 
F- ompT hsdSB(rB
- mB
-) gal dcm (DE3) pLysSRARE2 (CamR) 71403, Novagen  
 
 Recombinant and purified proteins 3.1.6
Protein Origin 
AAT, human Athens Research & Technology (Athens, GA, USA) 
Cathepsin G, human 219373, Calbiochem (Merck, Darmstadt, Germany) 
Neutrophil elastase, human Elastin Products (Owensville, MO, USA) 
Neutrophil elastase, mouse Therese Dau, AG Jenne 
Proteinase 3, human Diarect AG (Freiburg, Germany) 
Proteinase 3, mouse Therese Dau, AG Jenne 
Trypsin, bovine Sigma-Aldrich 
Kallekrein 3 AG Jenne 
Cathepsin B Recombinatnly expressed in Pichia pastoris, AG Jenne 
Cathepsin L Recombinatnly expressed in Pichia pastori, AG Jenne 
Cathepsin C Heike Kittel, AG Jenne 
Chymase 230780, Calbiochem (Merck, Darmstadt, Germany) 
NSP4 Natascha Perera, AG Jenne 
 Antibodies 3.1.7
Primary antibodies 
Antigen/ 
isotype control 
Species Clone 
Provider Cat. No. 
IgG1 Isotype Mouse - BD Biosciences 349040 
serpina2-G12 
polyclonal IgG 
Goat - 
Santa Cruz 109866 
SA2 mAb 6 Rat 4E10 AG Jenne/AG Kremmer IMI - 
SA2 mAb 75 Rat 5H4 AG Jenne/AG Kremmer IMI - 
SA2 mAb 76 Rat 3G6 AG Jenne/AG Kremmer IMI - 
SA2 mAb 77 Rat 2F6 AG Jenne/AG Kremmer IMI - 
SA2 mAb 80 Rat 2D11 AG Jenne/AG Kremmer IMI - 
SA2/AAT mAb 104 Rat 13C7 AG Jenne/AG Kremmer IMI - 
Ly6 mAb Rat IgG2a, κ 1A8 Biolegend 127601 
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Secondary antibodies 
Antigen Species Label Provider Cat. No. 
Rat IgG+IgM Goat HRP Jackson Immuno Research 112-035-068 
Goat Mouse HRP Millipore  
 
Other 
Protein Species Label Provider Cat. No. 
Avidin  HRP Invitrogen 434423 
 
 Synthetic substrates 3.1.8
FRET substrates 
Sequence Cleaving protease Provider  
5-TAMRA-EKAWSKYQ-Dap(CF) - EMC Microcollections  
5-TAMRA-EKPWSKPQ-Dap(CF) - EMC Microcollections  
TAMRA-VADnVRDYQ-Dap(CF) PR3 EMC Microcollections  
 
SBzl substrate 
Sequence Cleaving protease Provider  
Boc-APnV-SBzl PR3, NE Bachem  
 Cell line 3.1.9
The cell line HEK 293 EBNA1 was purchased from the NRC Biotechnology Research 
Institute (National Research Council in Montreal, Canada). 
 Mouse strains 3.1.10
We obtained pathogen-free C57BL/6J mice from Charles River.  
PR3/NE knockout animals (Ela2-/-Prtn3-/-) were established by Pfister et al.25. Mice were 
backcrossed for more than ten generations with C57BL/6J mice. All animals were kept under 
normal housing conditions with constant temperature and humidity, a 12 hour light cycle, and 
food and water were allowed ad libitum. 
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 Molecular biological methods 3.2
 Polymerase chain reaction (PCR) 3.2.1
PCR is a fast and easy method to specifically amplify a DNA fragment from very small 
amounts of template DNA. Two oligonucleotides flanking the two ends of the DNA 
fragment, which should be amplified, are used as Primers. They contain a free 3´-OH at 
one end, ensuring the synthesis of the new strand in only one direction. The synthesis is 
carried out by a Taq polymerase, which is stable at high temperatures. By adding and 
linking new nucleotides to the primers many copies of the amplicon are generated. PCR 
is carried out in several subsequent cycles, beginning with a denaturation step in which 
the strands of the DNA double helix separate from each other, followed by an annealing 
step in which the primers bind to the ends of the desired DNA fragment. All cycles are 
completed by a final extension step in which the DNA polymerase extends all DNA 
fragments to their full length. For all PCRs the HotStarTaq DNA Polymerase from Qiagen 
was used. 
HotStarTaq PCR reaction (25 μl): 
Component Concentration 
PCR buffer (Qiagen) 1x 
dNTP-mix (10 mM) 0.2 mM 
Forward primer (10 µM) 0.2 µM 
Reverse primer (10 µM) 0.2 µM 
HotStarTaq DNA polymerase 0.25 µl 
DNA template (1 ng/µl) 1 µl 
H2O up to 25 µl  
 
HotStarTaq PCR program: 
Pre-heating: 100 °C 
[°C] [s]   
95 30   
95 30 Denaturation  
50 - 65 60 Annealing 30 x 
72 75 Elongation  
72 300   
4 ∞   
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 Restriction (double) digest of PCR products 3.2.2
 
Restriction endonucleases are enzymes which cleave DNA at a specific recognition 
sequence. The DNA obtained from PCR was digested with one or two different restriction 
enzymes to produce linear fragments with non-complementary ends. To enable DNA ligation 
into a vector the plasmid is digested with the same enzymes as the PCR product. The 
reaction mixture consisted of the DNA-fragment, the restriction enzyme(s) and a buffer 
suitable for the enzymes. 1 µg DNA was digested with 10 U of the restriction enzymes. The 
mixture was incubated according to the manufacturers’ instructions . Restrictionenzymes 
were purchased from New England Biolabs or Thermo Fisher Scientific. 
 Agarose gel electrophoresis 3.2.1
DNA fragments are negatively charged due to their sugar-phosphate backbone and can 
therefore be separated in an agarose gel matrix in an electric field on the basis of their size. 
Agarose gels were prepared with TAE buffer supplemented with SYBR Safe (Life 
Technologies, dilution 1: 10000 ) to visualize DNA by exposure to UV light (254-366 nm). To 
prepare the gel, agarose (LE agarose, 840004 or Sieve 3:1 agarose, 850091, Biozym) was 
dissolved in TAE buffer by heating in a microwave for about 2 min. 0.8 – 4 % (w/v) agarose 
gels were casted depending on the fragment size to be analyzed. After addition of DNA 
loading buffer the samples were buffer, the samples were loaded into the gel slots and the 
gel was run in TAE-buffer at 80 V. To determine the size of the DNA fragments, the bands 
were compared to a molecular weight standard (Gene Ruler 1kb, Fermentas, Thermo Fisher 
Scientific). 
 
 
 
50 x TAE buffer 
 
Tris 242 g 
0.5 M EDTA pH 8.0 100 ml 
Acetic acid 57.1 ml 
H2O to 1 L  
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10 x DNA Loading buffer 
 
Bromphenol blue 0.25% (w/v) 
Xylenecyanol 0.25% (w/v) 
Glycerol 50% (w/v) 
 
 Dephosphorylation of vector DNA 3.2.2
To prevent the digested vector from self-ligation, it was dephosphorylated with the Calf 
Intestinal Alkaline Phosphatase (New England Biolabs). 1 µl of Alkaline Phosphatase 
was added to up to 5 µg of vector DNA in a restriction digest after 15 min and incubated for 
another 45 min at 37 °C.  
 DNA purification 3.2.3
Digested PCR products or vectors were purified by gel extraction (QIAquick GelExtraction 
Kit, Qiagen) or with the QIAquick PCR Purification Kit (Qiagen) in accordance with the 
manufacturer’s instructions. The final elution volume comprised 30-50 μL elution buffer or 
ddH2O, which was heated to 70 °C before elution for higher concentration results. 
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 Determination of DNA concentration 3.2.4
DNA concentrations were measured with the Nanodrop. Then 2 μl of the sample were 
pipetted onto the Nanodrop. For determination of DNA concentrations I measured the 
absorption at 260 nm. 
The theoretical fundament for this measurement is described by the Beer-Lambert law: 
𝐴 = lg
𝐼0
𝐼
= 𝑐 ∙  𝜀 ∙ 𝑑 
 
 Ligation 3.2.5
T4 DNA Ligase or the Quick Ligation Kit (both from New England Biolabs) were used to link 
the ends of the digested and dephosphorylated vector with the insert according to the 
manufacturer’s manual. Ligation reactions employing T4 DNA Ligase were carried out for 2-4 
h at room temperature or at 16 °C for 16 h. When using the Quick Ligation Kit the reaction 
mixture was incubated between 5-15 min at room temperature. For each reaction we took 50 
ng vector DNA and a molar ration of 5 to 10 of vector and insert in a total volume of 20 µl. 
Example of T4 DNA Ligase reaction mixture: 
Component 20 µl reaction 
Vector DNA (4 kb) 50 ng 
Insert DNA (1 kb) 37.5 ng 
T4 DNA Ligase 1 µl 
10X T4 DNA Ligase Buffer 2 µl 
ddH2O Up to 20 µl 
A…Absorption 
I0...intensity of incident light 
I…intensity of transmitted light 
c…concentration of absorbing particles 
ε…molar extinction coefficient 
d…thickness of sample 
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 Preparation of CaCl2-competent bacteria 3.2.6
5 ml of LB medium (Luria-Bertani-Broth) were inoculated with a single colony of E.coli DH5α 
and grown without the addition of antibodies in a 15 ml tube at 37 °C with shaking (250 rpm) 
overnight. On the next day 4 ml of the pre-culture were added to 400 ml fresh LB medium. 
The cells were incubated (37 °C, 250 rpm) until the OD600 reached 0.4, which took 
approximately three hours. Then, the bacterial suspension was pre-cooled on ice in 50 ml 
tubes for 10 min. Subsequently, the suspensions were pelleted by centrifugation without 
break (7 minutes, 3000 rpm, 4 °C). For all remaining steps the cells were kept on ice and all 
flasks, pipette tips and tubes were pre-cooled at 4 °C. Cell pellets of 100 ml culture volume 
were resuspended in 10 ml ice-cold CaCl2 buffer and centrifuged again (5 min, 2500 rpm, 4 
°C, no brakes). Cell pellets were again resuspended in 10 ml ice-cold CaCl2 buffer and 
incubated on ice for 30 min followed by centrifugation (5 min, 2500 rpm, 4 °C, no brakes). 
Bacteria pellets were resuspended in 2ml ice-cold CaCl2 buffer and 150 µl aliquots were snap 
frozen in liquid nitrogen and stored at -80 °C. 
CaCl2 buffer  
CaCl2 60 mM 
PIPES 10 mM 
Glycerol 15% (w/v)  
pH 7  
 
LB medium 
 
Bacto tryptone 1% (w/v) 
Yeast Extract 0.5% (w/v) 
NaCl 1% (w/v) 
pH 7.5, autoclaved  
 
LB agar plates 
 
LB medium 1 L 
Bacto agar 1.5% (w/v) 
autoclaved  
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 Transformation of CaCl2-competent bacteria  3.2.7
Competent E. coli DH5α were thawed on ice for 10 min. Transformation of plasmid DNA into 
competent E.coli cells was performed by mixing 100 μl of competent bacteria cells with 5 μl 
of the ligation reaction followed by incubation on ice for 30 min. This allows the plasmid DNA 
to attach to the cell wall of the bacteria. A heat-shock was performed for 45 sec at 42 °C in a 
water bath, and then the tube was immediately chilled on ice for about 10 min. The heat-
shock permeabilizes the cell membrane for a short duration and the plasmid DNA can enter 
the bacteria. After that 900 μl of LB medium were added, followed by incubation for 1 h at 37 
°C in a shaking thermoblock. 200 μl cell suspension was plated on LB agar plates containing 
the respective antibiotics and incubated overnight at 37 °C. 
 DNA Sequencing 3.2.8
In order to check whether plasmids with a positive restriction digest result contain any 
mutations they were sequenced by Eurofins MWG GmbH (Ebersberg, Germany). 
 Plasmid DNA purification from bacteria 3.2.9
Purification of Plasmid DNA from 5 ml E.coli overnight culture was carried out with the 
QIAprep Spin Miniprep Kit (Qiagen). After alkaline lysis of the bacterial cells the DNA 
was bound to a silica membrane in high salt. For the purification of higher amounts of 
Plasmid DNA out of larger overnight cultures the PureYield™ Plasmid Maxiprep System 
(Promega) was utilized. Furthermore, this purification procedure included an endotoxin 
removal step to remove protein, RNA and endotoxin contaminants from the DNA 
preparation. Both kits were used according to the manufacturer’s protocol. The purified 
and endotoxin free plasmid DNA was used for transfection of mammalian cells (HEK 
293EBNA). Removal of endotoxin was necessary to avoid reduced transfection 
efficiency. 
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 Glycerol cultures 3.2.10
Glycerin cultures were established for permanent stocking of bacteria cultures. For this 
purpose an overnight culture of bacteria was grown in 3 ml LB in a 15 ml tube at 37 °C with 
shaking. Then, the bacteria cell suspension was centrifuged (4000 rpm, 10 min). Autoclaved 
glycerol (87%) and LB was added to the bacteria pellet to get a 15 – 20 % final concentration 
of glycerol in a cryotube. The tube was snap frozen in liquid nitrogen and stored at – 80 °C. 
 Quantitative real-time RT-PCR analysis 3.2.11
cDNA of 46 healthy human tissues (Cat. No.: HMRT 102) and a human brain panel (Cat. No. 
HBRT 101) were obtained from OriGene Technologies and cDNA of a human 
megakaryoblastic leukemia cell line, MEG-01, was purchased at ECACC (Cat.No.94012401). 
Quantitative PCR was performed using the SYBR Green LC480 System (Adhesive clear 
PCR seal: 600208, 96 well plate, white: 712282, Biozym, LC 480 Cycler: Roche Diagnostics, 
Mannheim, Germany). For detection of serpina2 we used the following primer pair: DJ3701 
and DJ3702 (see 3.1.3). GAPDH primers (OriGene Technologies, Cat. No.: HMRT 102, 
included in kit) were used as intrinsic control for normalization of the results. 
 Serpina2 genotyping of human blood samples 3.2.12
Whole blood (100 µl) was used to extract DNA with the DNeasy Blood and Tissue Kit (69506, 
Qiagen). During the isolation procedure 20 µl of proteinase K (20 mg/ml) were added to 100 
µl whole blood diluted in 100 µl PBS. DNA was eluted in 100 µl elution buffer. Whether the 
isolation was successful, was determined by measuring the DNA concentration with the 
Nanodrop. DNA yield ranged from 10 – 20 ng/µl. 
As a first step, a PCR with the KAPA2G Fast Genotyping Mix (KK5121, Roche) was carried 
out to amplify the serpina2 DNA fragment. 
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Serpina2 genotyping PCR reaction (25 μl): 
Component [µl] Final concentration 
KAPA Mix 12.5  
DJ3754, forward primer (10 µM) 1.25 0.5 µM 
DJ3751, reverse primer (10 µM) 1.25 0.5 µM 
DNA template (10 – 20 ng/µl) 1  
H2O  9  
 
Serpina2 genotyping PCR program: 
Pre-heating: 100 °C 
[°C] [s]   
95 180   
95 15 Denaturation  
58 20 Annealing 35 x 
72 30 Elongation  
72 600   
4 ∞   
 
 
The second step was to digest the PCR product with the two restriction enzymes in separate 
reactions. Digestion with BsmI (R0134S, NEB) was used to identify serpina2 deletion 
genotypes and BseLI (ER1201, Thermo Fisher Scientific) was used to identify serpina2 fs108 
genotypes. Reaction mixtures were incubated at 60°C for two hours. 
Digestion reaction (13 µl): 
Component [µl] 
PCR  7 
10 x Tango buffer 1.3 
BseLI 1 
H2O  4.6 
 
Component [µl] 
PCR  7 
10 x Cut smart 1.3 
BsmI 1 
H2O  4.6 
 
Subsequently, the digested PCR products were analyzed on a 4 % agarose gel (Sieve 3:1 
agarose, 850091, Biozym) by electrophoresis for 2 hours at 85 V. 
  
3 Materials and methods 
20 
 
 Recombinant protein expression 3.3
 Serpina2 expression in E.coli 3.3.1
For the expression of serpina2 we used competent E.coli BL21(DE3) (C2527I, NEB). DE3 
indicates that the host (lysogen of λDE3) carries a chromosomal copy of the T7 RNA 
polymerase gene under control of the lacUV5 promoter and can therefore be induced with 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) for production of protein from target genes 
cloned in pET vectors. We also utilized two enhanced BL21 derivatives: the SHuffle® 
Express(C3028J, NEB) strain, engineered to promote disulfide bond formation in the 
cytoplasm and the Rosetta™ 2(DE3)pLysS (71403, Novagen) designed to enhance the 
expression of eukaryotic proteins that contain codons rarely used in E. coli. pLysS strains 
express T7 lysozyme, which further suppresses basal expression of T7 RNA polymerase 
prior to induction, thus stabilizing pET recombinants encoding target proteins that affect cell 
growth and viability. 
For overexpression of recombinant proteins, competent E.coli cells were transformed with 
different serpina2 plasmids (pET_24c_serpina2_His, pET24c_His_SUMO_serpina2, and 
PQEwa_His_TEV_serpina2). Cells were grown at 37 °C in LB medium in the presence of the 
appropriate antibiotics until the OD600 reached 0.6 – 0.8. Then IPTG was added to a final 
concentration of 0.5 mM to induce protein expression. After growth for 16 h at 18 °C or 37 °C 
the cells were harvested by centrifugation. 
Supplement Stock solution In media diluted to 
Ampicillin 100 mg/ml in H2O 100 µg/ml 
Kanamycin 30 mg/ml in H2O 30 µg/ml 
IPTG 234.3 mg/ml (1 M) in H2O 0.5 mM 
 
 Expression of AAT and AAT variants in HEK 293 cells 3.3.2
Before transfection HEK 293 cells were grown to a density of 1 x 106 cells/ml. 
Polyethyleneimine (PEI) a cationic polymer, that binds to negatively charged DNA, was used 
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for the generation of PEI/DNA complexes.30 µl of PEI were added to 500 µl of Optipro serum 
free medium (Invitrogen) and 7.5 µg of plasmid DNA were added to 500 µl Optipro in a 
separate tube. Both mixtures were combined and incubated at room temperature for 20 min. 
The PEI/DNA mixture was added drop-by-drop to 15 ml (15 million cells) cell suspension to 
ensure equal distribution of the DNA. The cells were incubated at 37 °C and after 24 hours 
Bacto TC Lactalbumin Hydrolysate (BD Biosciences), which is the enzymatically hydrolyzed 
portion of milk whey, was added as an amino acid supplement to 0.5% final concentration. 
Supernatants were harvested after 4 days by centrifugation (1500 rpm/10 min/ 4 °C). 
 Protein analysis 3.4
 Purification of recombinant proteins by Ni-NTA 3.4.1
First, the cell culture supernatant was filtered through a 0.22 µm membrane (Millipore). For 
proteins with lower expression rate, the supernatant was concentrated using a ultrafiltration 
membrane with 10 kDa cut-off (Amicon Ultra centrifugal filter, UFC801024, Merck). Then, the 
supernatant was dialyzed against Ni-NTA binding buffer. The dialyzed supernatant was 
again filtered (0.22 µM) and the protein solution was applied to a HisTrap HP column (GE 
Healthcare) previously equilibrated in binding buffer. The column was washed with binding 
buffer, and bound proteins were eluted applying a linear imidazole gradient from 50 mM to 1 
M imidazole in binding buffer. Fractions were collected and analyzed by SDS-PAGE and 
coomassie or silver staining. The fractions that contained the protein of interest were pooled 
and concentrated. 
Ni-NTA binding buffer 
 
Na2HPO4 20 mM 
NaCl 300 mM 
Imidazole 10 - 20 mM  
pH 7.4  
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Ni-NTA elution buffer 
 
Na2HPO4 20 mM 
NaCl 300 mM 
Imidazole 1 M  
pH 7.4  
 
 Purification of recombinant protein by anti-His immunoaffinity  3.4.2
After Ni-NTA affinity purification, some recombinant proteins were subjected to a second step 
of purification to get rid of contaminations by non-specifically binding proteins. An anti-His 
affinity resin (Cat.No. L00439-1, GenScript) was used according to the manufacturer’s 
protocol. We chose to use an acidic elution procedure. 
Anti-His affinity resin binding buffer 
 
Tris HCl 50 mM 
NaCl 150 mM 
pH 7.4  
 
Anti-His affinity resin elution buffer 
 
Glycine HCl 0.1 M 
pH 2.5  
 
Anti-His affinity resin neutralization buffer 
 
Tris 1 M 
pH 9.0  
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 Determination of protein concentration 3.4.3
The concentration of protein solutions was either assessed by a bicinchonic acid (BCA) 
assay carried out according to the manufacturer’s instructions, or by spectrophotometrically 
measurement of absorbance at 280 nm. The concentration can be calculated using the Beer-
Lambert law (see 3.4.3). 
The extinction coefficient of each protein was determined by using the ProtParam tool 
(http://us.expasy.org/tools/ protparam.htm) inserting the protein sequence obtained from the 
UniProt database (http://www.uniprot.org/). 
 Sodium dodecyl sulfate - polyacrylamide gel electrophoresis (SDS-PAGE) 3.4.4
To separate proteins according to their size we used SDS-PAGE. We use self-made 
discontinuous gels, which consist of a stacking gel and a resolving gel. In the stacking gel the 
proteins form thin sharp bands due to the slightly acidic milieu and the low concentration of 
acrylamide. Then they enter the resolving gel, which has a more basic pH and a higher 
polyacrylamide concentration that leads to the separation of the proteins according to their 
size. Both, the samples and the gel/gel running buffer contain the detergent SDS, which 
denatures the proteins. They unfold into their secondary structure and get negatively charged 
according to their size. The sample buffer contains also ß-mercaptoethanol which is able to 
reduce disulfide bonds. Before loading, the protein samples were denatured by incubation in 
sample buffer at 95°C for 5 min, and then were centrifuged for 1 min at 12 000 rpm. For 
analysis, up to 20 µl of sample and 10 µl of protein marker (Prestained Protein Marker, 
Broad Range, New England Biolabs) were loaded. 
Sample buffer 4 x, reducing 
 
Tris 200 mM 
Glycine 200 mM 
SDS 1 mM 
MeOH 20% 
pH 6.8  
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 Protein detection 3.4.5
Coomassie staining 
After SDS-PAGE gels were incubated for 1 h in Coomassie staining solution. To remove 
unspecific staining the gel was incubated Coomassie destaining solution until protein bands 
were visible. The gels were photographed with a Chemidoc imaging system (Bio-Rad). 
Coomassie staining solution 
 
Coomassie Brilliant Blue 0.25 % (w/v) 
Methanol 45 % (v/v) 
Acetic acid 10 % (v/v) 
 
Coomassie destaining solution 
 
Methanol 45 % (v/v) 
Acetic acid 10 % (v/v) 
 
Silver nitrate staining 
After SDS-PAGE the gel was incubated in fixation solution for 1 h at room temperature while 
shaking. Subsequently, it was washed three times in 50% ethanol for 20 min, then the gel 
was incubated in thiosulfate solution for 1 min for sensitization, then rinsed in tap water three 
times for 20 sec. After incubation in silver nitrate solution for 20 min, the gel was again 
washed three times for 20 sec in tap water, and then the gel was kept in development 
solution until protein bands became visible. To stop the staining reaction the gel was quickly 
rinsed in tap water and then incubated in stopping solution for at least 20 min. After the 
stopping solution was replaced with tap water, the gels were photographed with a Chemidoc 
imaging system (Bio-Rad). 
Fixation solution 
 
Methanol 50 % (v/v) 
Acetic acid 12 % (v/v) 
Formaldehyde 37% 0.5 ml/l 
 
Thiosulfate solution 
 
Na2S2O3 x 5 H2O 0.2 g/l 
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Silver nitrate solution 
 
AgNO3 2 g/l 
Formaldehyde 37% 0.75 ml/l 
 
Development solution 
 
Na2CO3 60 g/l 
Na2S2O3 x 5 H2O 4 mg/l 
Formaldehyde 37% 0.5 ml/l 
 
Stopping solution 
 
Methanol 50 % (v/v) 
Acetic acid 12 % (v/v) 
 
 Measurement of enzymatic activity 3.4.6
3.4.6.1 Förster/Fluorescence resonance energy transfer (FRET) 
FRET substrates mimicking the RCL of serpina2 were developed to test cleavage by 
potential target proteases of the serpin. The TAMRA-FRET substrates (see 3.1.8) were 
diluted in DMSO to reach a concentration of 100 µM.  
Typical reaction: 
Component [µl] Final concentration 
Activity assay buffer 40  
Protease 1 µM 5 0.1 µM 
FRET substrate 100 µM 5 10 µM 
Final volume 50  
 
Activity assay buffer 
 
Tris 50 mM 
NaCl 150 mM 
Triton X-100 0.01 % 
pH 8.0  
 
The reaction components were combined in a microtiter plate and the hydrolysis rate of the 
FRET peptides was followed by measuring the fluorescence (λEx = 485 nm and λEm = 520 
nm). Specificity was assessed by recording the increasing fluorescence over time for each 
substrate. Only the slope of the reaction curve was used to define the enzymatic activity in 
RFUs (relative fluorescent units). 
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3.4.6.2 Assay for inhibitory activity measurement 
The enzymatic activities of the serine proteases, NE and PR3, were determined using 
thiobenzyl ester substrates and Ellman’s reagent (5,5’-dithiobis-(2-nitrobenzoic acid) or 
DTNB). Free thiobenzylester groups react with DTNB and form yellow 2-nitro-5-thiobenzoate 
ions. The rate of hydrolysis was measured at 405 nm. Inhibitory activities of 0.5 µM AATwt 
and AATmt were tested in an activity assay using 0.1 µM recombinant mouse or human NE 
or PR3. The remaining activity of the proteases was determined using thiobenzyl ester 
substrate (see 0) at 1 mM substrate concentration and 0.5 mM DTNB in activity assay buffer 
(see 3.4.6.1). 
 Deglycosylation of protein with Endo H and PNGase 3.4.7
To monitor protein trafficking and comparison of size of unmodified protein from different 
species we deglycosylated protein with PNGase F (P0704S, NEB) and Endo H (P0702S, 
NEB) according to the manufacturer’s protocol. PNGase F, an amidase, cleaves off high 
mannose, hybrid, and complex oligosaccharides of N-linked glycoproteins between the 
innermost GlcNAc and asparagine residues. Endo H can cleave high mannose and hybrid 
glycans, but fails to hydrolyse complex glycans, this modification takes place when a protein 
successfully entered the Golgi apparatus. Proteins containing glycans resistant to Endo H 
must have entered the Golgi apparatus. 
 Mass Spectrometry (MS) – Sample preparation and analysis 3.4.8
3.4.8.1 Preparation for immunoprecipitated MS samples 
MS has become the method of choice for protein detection. For sample preparation we 
immunoprecipitated serpina2 in protein lysates (RIPA buffer) using the monoclonal 
antibodies established in this work (mAb 75 and mAb 80), and Dynabeads™ Protein G for 
immunoprecipitation (10003D, Thermo Fisher Scientific) according to the manufacturer’s 
protocol. Subsequently, the proteins on the beads were treated with 20 µl lysis buffer. The 
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buffer contained guanidinium, a strong chaotropic agent, that denatures proteins, and 
reducing agent TCEP (tris(2-carboxyethyl) phosphine) to hydrolyze disulfide bonds. The free 
sulfhydryl groups on the cysteine residues are then alkylated with chloroacetamide to prevent 
reformation of disulfide bonds. Then the reduced and alkylated proteins were diluted 1:10 in 
digestion buffer and digested with Lys-C (200 ng) and Trypsin (200 ng) overnight at 37 °C. 
After digestion each sample was acidified to a final concentration of 1% trifluoroacetic acid.  
We purified the proteins using stage tips containing SDB-RPS material (poly(styrene-
divinylbenzene) copolymer modified with sulfonic acid groups). SDB-RPS material was used 
to plug 200 µl pipette tips and activated wit 100 µl acetonitrile. Subsequently, it was 
equilibrated with 100 µl equilibration buffer followed by 100 µl containing 0.2% trifluoroacetic 
acid. Then the sample (in 1% trifluoroacetic acid) was loaded onto the stage tip, and washed 
with 100 µl containing 0.2% trifluoroacetic acid. Peptides were eluted with 60 µl elution buffer 
into a PCR tube. After elution the samples were concentrated with speed-vacuum until no 
liquid was left and all peptides stuck to the wall of the PCR tube. The peptides were 
dissolved in measurement buffer and sonicated for 10 min in a water bath. Samples were 
stored at -20 °C before analysis. 
 
Lysis buffer 
 
Guanidinium Chloride 6 M 
TCEP 10 mM 
Chloroacetamide 40 mM 
Tris  100 mM 
pH 8.5  
 
Digestion buffer 
 
Acetonitrile 10% 
Tris pH 8.5 25 mM 
 
 
Equilibration buffer for SDB-RPS tips 
 
Methanol 30% 
Trifluoroacetic acid 1% 
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Elution buffer for SDB-RPS tips 
 
Ammonia (25%) 5% 
Acetonitrile 80% 
 
Measurement buffer 
 
Acetonitrile 2% 
Trifluoroacetic acid 0.1% 
 
3.4.8.2 Sample preparation for whole tissue lysate analysis:  
Samples (10µg each) were subjected to tryptic digest using a modified filter-aided sample 
preparation (FASP)26,27. After centrifugation samples were acidified with 100 % trifluoroacetic 
acid. (Sample preparation for whole tissue lysate analysis was carried out by the Core 
Facility Proteomics at the Helmholtz Center Munich.) 
3.4.8.3 MS measurement: 
Mass spectrometry measurement was either performed in data dependent (DDA) or data 
independent (DIA) mode by the Core Facility Proteomics at the Helmholtz Center Munich. 
MS data were acquired on a QExactive (QE) high field (HF) mass spectrometer (Thermo 
Fisher Scientific Inc.). Each sample (0.5 µg) was loaded automatically onto the on online 
coupled RSLC (Ultimate 3000, Thermo Fisher Scientific Inc.) HPLC system. A nano trap 
column (300 μm inner diameter × 5 mm, column material: Acclaim PepMap100 C18, 5 μm, 
100 Å; LC Packings, Sunnyvale, CA) was utilized before separation by reversed phase 
chromatography (Acquity UPLC M-Class HSS T3 Column 75µm ID x 250mm, 1.8µm; 
Waters, Eschborn, Germany) at 40°C. Peptides were eluted from the column at 250 nl/min 
using increasing acetonitrile concentrations (in 0.1% formic acid) from 3% to 41 % over a 105 
minutes gradient. 
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DDA method and analysis: 
The high-resolution MS spectrum (60,000 full width at half-maximum) was acquired with a 
mass range from 300 to 1500 m/z with automatic gain control target set to 3 x 106 and a 
maximum of 50 ms injection time. The 10 most abundant peptide ions from the MS pre-scan 
were selected for fragmentation (MS/MS) if at least doube-charged, with a dynamic exclusion 
of 30 seconds. MS/MS spectra were recorded with automatic gain control target set to 1 x 
105 and a maximum of 100 ms injection time (resolution: 15,000). All spectra were recorded 
in profile type and the normalized collision energy was set to 28. 
Qualitative data analysis for DDA with Scaffold software: 
Scaffold software (Proteome software, Version 4.7.2) was used for spectra analysis. We 
searched against the Swissprot human database (Release 2017.02 containing 553474 
sequences) and a few complementary proteins for spiking. Search parameters used were set 
to 10 ppm peptide mass tolerance, and 20 mmu fragment mass tolerance. 
Carbamidomethylation of cysteine was set as fixed modification and oxidation of methionine 
and deamidation of asparagine and glutamine was allowed as variable modification, with only 
one missed cleavage site. Mascot integrated decoy database search was set to a false 
discovery rate (FDR) of 1 % with a percolator ion score cut-off of 13 and an appropriate 
significance threshold p. 
Qualitative data analysis for DDA with MaxQuant software: 
MaxQuant software (version 1.4.1.12, Cox & Mann, 2008) was used to analyze raw files. 
Peak lists were searched against the human UniProt FASTA database (version August 
2017), and a database of common contaminants (247 entries) by the Andromeda search 
engine (Cox et al, 2011). Carbamidomethylation of cysteine was set as fixed modification 
and oxidation of methionine and deamidation of asparagine and glutamine was allowed as 
variable modification, with only one missed cleavage site. False discovery rate was set to 
0.01 for peptides and proteins, which allows a minimum peptide length of seven aa. It was 
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determined by searching a reverse database. In the database search enzyme specificity was 
set as C-terminal to arginine and lysine, and we allowed a maximum of two missed 
cleavages. For peptide identification we accepted a precursor mass deviation up to 4.5 ppm 
after time-dependent mass calibration and a fragment mass deviation of up to 20 ppm. The 
minimum ratio count was set to two for label-free quantification in MaxQuant (MaxLFQ28). 
The retention time alignment window was set to 30 min for matching between runs (match 
time window 1 min). 
HRM DIA method and analysis: 
We started with a survey scan from 300 to 1650 m/z and an automatic gain control target of 
120 ms maximum injection time (resolution: 120,000). Fragmentation was performed via 
higher energy collisional dissociation with a target value of 3e6 ions determined with 
predictive automated gain control. Precursor peptides were isolated with 37 variable windows 
spanning from 300 to 1650 m/z with an automated gain control target of 3e6 and automatic 
injection time (resoulution: 30,000). The normalized collision energy was 28 and the spectra 
were recorded in profile type.  
Spectral library for DIA measurement: 
A special peptide spectral library containing serpina2 with 25 unique peptides equaling a 
protein coverage of 56% was generated in Spectronaut (Version 10, Biognosys) with default 
settings using the Proteome Discoverer combined result file. Spectronaut was equipped with 
the Swissprot human database. The final spectral library generated in Spectronaut contained 
151 protein groups and 1261peptide precursors. 
Spectronaut analysis of DIA measurement: 
The DIA MS data was analyzed using the Spectronaut 10 software applying default settings 
with the exception: quantification was limited to proteotypic peptides; data filtering was set to 
Q-value 25% percentile, summing-up peptide abundances. 
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 Cell biological methods 3.5
 Determination of cell count and viability 3.5.1
A hemocytometer (Neubauer improved) was used to count the number of viable cells. For 
this purpose 10 µl of cell suspension were mixed with 10 µl Trypan blue buffer and all viable 
cell were counted in the four quadrants. Dead cells have perforated membranes; Trypan blue 
can enter into the cytoplasm and stains these cells blue. The average number of cells in one 
quadrant (100 nl) was multiplied with the dilution factor and by 104 to determine the number 
of cells/ml. 
 
Trypan blue buffer 
 
Trypan blue 0.1% (w/v) 
PBS  
pH 7.4  
 
 Isolation of PMNs and PBMCs from human blood 3.5.2
To carry out a hypotonic granulocyte lysis 18 ml (2 x 9 ml in EDTA tubes, BD 
Biosciences) fresh blood was drawn from a healthy volunteer and pipetted into a 50 ml 
tube. Additionally, PBS was added to a final volume of 35 – 40 ml. To create a density 
gradient Pancoll (17-0891-01, GE Healthcare) was very carefully added to the bottom of 
the 50 ml tube with a disposable pipette. The tube was centrifuged (20 min, 20 °C, 500 x 
g, without brake!) and the forming layers were carefully removed. The plasma was 
discarded, the lymphocytes – or peripheral blood mononuclear cells (PBMCs) were 
stored in a separate tube, the Pancoll was discarded and the erythrocytes and 
granulocytes (polymorphonuclear cells – PMNs) at the bottom of the tube were diluted in 
PBS to a final volume of 40 ml. To create a dextran gradient 8 ml of 6 % dextran were 
added to the solution. Erythrocytes pass the dextran gradient, whereas granulocytes stay 
in solution, after 30 min of sedimentation at room temperature the granulocyte rich 
supernatant was transferred to a separate tube and centrifuged (5 min, 4 °C, 500 x g). 
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The supernatant was discarded and the granulocyte pellet was washed with 5 ml 0.2 % 
NaCl solution for 1 min to lyse the remaining erythrocytes. Then, 5 ml 1.6% NaCl were 
added for another minute and the solution was filled up to 30 ml with PBS. After a final 
centrifugation step (5 min, 4 °C, 500 x g) the PMNs were resuspended in PBS and stored 
at -20 °C. 
 Preparation of total cell lysates 3.5.3
For the lysis of PMNs or PBMCs, cells were resuspended in cold RIPA 
(radioimmunoprecipitation assay) buffer (12 µl/106 cells). After incubating on ice for 20 min 
and sonification (four times 5 min, plus 5 min cooling step between sonification steps) the 
samples were centrifuged (10 min, 4 °C, 20 000 x g). Cell debris and DNA remained in the 
pellet, while the supernatant was transferred to a new tube.  
RIPA buffer 
 
Tris 50 mM 
NaCl 150 mM 
EDTA 1 mM 
Deoxycholic acid 0.5% (w/v) 
SDS 0.1 % (w/v) 
Nonidet P-40 (Igepal) 0.5% (w/v) 
pH8.0  
 
 Immunological methods 3.6
 Immunoblotting 3.6.1
For immunoblotting, proteins were transferred onto a polyvinylidene difluoride (PVDF) 
membrane, activated in 100% methanol for 20 sec, using a semi-dry transfer machine. The 
‘sandwich’ consisted of one layer of Whatman paper followed by the PVDF membrane, the 
SDS-PAGE gel and another layer of Whatman paper. All components were soaked in 
transfer buffer and assembled on the transfer machine. The proteins were transferred at 200 
mA for 50 min. The membrane was then blocked for 1 h at room temperature, and incubated 
with the primary antibody diluted in blocking buffer overnight at 4°C with shaking. After 
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washing the membrane three times for 10 min with PBS-T at room temperature, the 
membrane was incubated with the appropriate HRP-conjugated secondary antibody at room 
temperature for at least 1 h, and washed again four times for 5 min with PBS-T. Proteins 
were detected with the Super Signal® West Pico Chemiluminescent Substrate (#34080, 
Thermo Scientific). 750 µl of both Solution A (Luminol Enhancer Solution) and Solution B 
(Stable Peroxide Solution) were mixed and immediately added to the membrane for a two 
min incubation. The membrane was developed by using the Chemidoc imaging system (Bio-
Rad). 
Transfer buffer 
 
Tris 25 mM 
Glycine 200 mM 
SDS 1 mM 
MeOH 20% 
 
PBS-T 
 
NaCl 140 mM 
KCl 3 mM 
Na2HPO4 x 12 H2O 8 mM 
KH2PO4 1 mM 
Tween-20 0.05% (v/v) 
pH 7.4  
 
Blocking buffer 
 
Non-Fat Dry Milk Blocker 5% (w/v) 
PBS-T  
 
 Enzyme-linked immunosorbent assay (ELISA) 3.6.2
A sandwich ELISA was established and performed to measure serpina2 in human samples. 
First, the detection antibody (mAB 75) was coated onto a 96 well plate at a concentration of 1 
µg/ml in coating buffer at 4 °C overnight. In between all following steps, the plate was 
washed with three times 200 µl PBS-T (see 3.6.1) and all incubation steps were carried out 
at room temperature in a humid chamber. Wells were blocked for one hour in 200 µl blocking 
buffer to prevent unspecific binding. Subsequently, the samples (diluted 1:10 with blocking 
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buffer) were incubated for 1.5 h. For detection the biotinylated mAB 80 was added (100µl, 1 
µg/µl) and incubated for 1.5 h, and then Avidin-HRP (dilutied 1: 3000 in blocking buffer) for 1 
h. For development of the ELISA TMB substrate (Cat.No. T4444, Sigma-Aldrich) was added 
and incubated up to 20 min. The OD values were measured at λ=370 nm. 
Biotinylation of mAb80: 
A 20 nM solution of Sulfo-NHS-Biotin (Cat.No. 2322-50, Biovision) in DMSO was added to 
IgG solution (2 mg/ml) with 20 fold molar excess and incubated for 1 h at room temperature. 
Then the biotinylated antibody solution was dialyzed against PBS to get rid of excess Biotin. 
 
Coating buffer 
 
Na2CO3 10 mM 
NaHCO3 10 mM 
 
Blocking buffer 
 
NaCl 140 mM 
KCl 3 mM 
Na2HPO4 x 12 H2O 8 mM 
KH2PO4 1 mM 
Tween-20 0.05% (v/v) 
BSA 2% (w/v) 
pH 7.4  
 
 Immunohistochemistry 3.6.3
Sections containing lung tissue slices were sequentially incubated for 20 minutes at 65 °C. 
Then they were sequentially transferred to 100% xylene, then 100%, 90%, 80% and 70% 
ethanol, followed by tap water for 5 min, and rinsed in distilled water. Antigen retrieval was 
performed in 0.01 M citric acid pH 6.0 in a cooker chamber for 30 minutes at 125°C. Tissue 
was rehydrated with PBS-Tween 20 (0,1%) for 10 min. Endogenous peroxidases were 
quenched by incubation in 3% H2O2 (30%, H1009, Sigma Aldrich) in PBS for 10 min. After 
washing with PBS and PBS-Tween 20 (0,1%) avidin solution (Avidin/Biotin Blocking Kit, SP-
2001; Vector Laboratories) was added and incubated for 15 min, followed by washing with 
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PBS-T (1x PBS-Tween 20 0,1%); biotin solution was added for 15 min, washed with PBS-T; 
nonspecific antibody-binding sites were blocked with blocking solution, PBSA (BSA 3% in 
PBS) for 1 h, and sections were incubated for 1.5 h with the specific primary antibody diluted 
in blocking buffer. Sections were stained with monoclonal rat mouse-specific Ly-6G 
monoclonal antibody (working dilution 1:200, clone 1A8, Biolegend) for detection of 
neutrophils. After washing in PBS-T, visualization was performed via incubation with HRP-
conjugated secondary antibody with goat rat-specific IgG (H+L), biotin conjugated (working 
dilution 1:250, Thermofisher) for 30 min at room temperature followed by addition of the 
corresponding peroxidase substrate (ImmPACT DAB Peroxidase (HRP) Substrate, SK-4105; 
Vector Laboratories). After counterstaining with hematoxylin, dehydration and mounting, the 
sections were scanned using the Axio Imager (Imager.M2, Zeiss). High resolution images, 
which were taken at the same magnification and areas were randomly chosen and 
microscopically analyzed for neutrophil counting. The mean number of at least ten images 
was used for quantification. 
 Mouse model analysis (AAT in transplantation) 3.7
 Study approval 3.7.1
All animal experiments were conducted under strict governmental and international 
guidelines and were approved by the local government for the administrative region of Upper 
Bavaria (Project 55.2–1-54-2532-120-2015). 
 Orthotopic lung transplantation model 3.7.2
Orthotopic lung transplantation was performed as described by Krupnick et al. with minor 
modifications29. C57BL/6J mice (male, 8-12 weeks old) were utilized as donors, and 
C57BL/6J and Ela-/-Pr3-/- mice (male, 8-12 weeks old) were utilized as recipients. In brief, 
donors were anesthetized with a mixture of ketamine/xylazine injected intraperitoneally. The 
pulmonary artery (PA), bronchus (BR) and pulmonary vein (PV) were separated with blunted 
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forceps, prior to cuffing with, 24G, 20G and 22G cuffs, respectively. The left lung lobe was 
perfused intravenously with Perfadex (3 ml). Subsequently, it was perfused with Perfadex 
supplemented with protein at a concentration of 1 mg/ml (Albumin, AATwt or AATmt). The PA 
and PV were clamped with Biemer micro vessel clips (Bbraun), in order to keep the solution 
inside the blood vessels, and it was stored for 18 hours at 4°C before implantation. The 
recipient was anesthetized with a medetomidine/midazolam/fentanyl (1/0.05/0.02 mg/kg), 
intubated, and connected to a small animal ventilator (Harvard Apparatus), at a respiratory 
rate of 120 bpm and a tidal volume of 300 μL. The chest was incised on the left side between 
rib 3 and rib 4 and the native left lobe of the mouse lung retracted with a clamp. The hilar 
structures were carefully separated with blunted forceps. The donor lung graft, prepared 18 
hours earlier, was perfused intravenously with Perfadex to rinse out the storage solution. 
After arrest of the blood and air flow towards the left lung, the cuffed graft PA, BR and PV 
were inserted into the recipient counterparts, and the connection was secured with 9-0 
sutures. The native left lung was removed and the incision in the chest was closed with a 6-0 
suture, after removing all potential air bubbles from the chest. After administration of 
antagonist the animal was extubated at the first signs of spontaneous breathing. After the 
operation, the recipients were allowed to recover at 30 °C and received buprenorphine (0.1 
mg/kg). The mice were sacrificed four hours after transplantation for PGD assessment. 
 Allograft tissue sample collection (blood gas, bronchoalveolar lavage) 3.7.3
The recipient was anesthetized with a mixture of medetomidine/midazolam/fentanyl 
(1/0.05/0.02 mg/kg) four hours after lung surgery. After intubation (300 µl room air/120 
strokes/min), a midline abdominal incision was executed, the diaphragm incised and the 
chest opened to lay bare the lung and heart block. The right bronchus and pulmonary vein 
were clamped for 5 min (75 µl room air /120 strokes/min) and the oxygenation function of the 
transplanted left lobe was determined by collection of blood from the left ventricle of the heart 
and direct measurement of the pO2 [%] in a blood gas analyzer (ABL80 FLEX CO-OX 
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analyzer, Radiometer). Subsequently, with the right bronchus still clamped, BAL of the 
transplanted left lung was collected by instilling cold PBS (three times, 200 µL) into the 
trachea. The BALF was obtained by centrifugation (400 g, 20 min, 4°C) and protein 
concentration was measured with the Pierce™ BCA Protein Assay Kit (catalog no. 23225, 
Thermofisher). 30.000 cells from the BAL cell pellet were used for a cytospin (200 x g, 6 min, 
4°C) and stained with May Grünwald (1424, Merck) and Giemsa (Merck, 9204) solution in 
order to perform a differential cell count. The lower part of the lung was kept separately for 
protein analysis (snap freezing, storage at -80 °C) and the remaining upper part was utilized 
for histology (inflation with and storage in 4% PFA). 
 Western blot analysis of transplanted lung lysates 3.7.4
Whole lung tissues were subjected to a tissue disrupter in liquid nitrogen to form fine tissue 
powders of each lung. Subsequently, the powder was dissolved in cold RIPA buffer (see 
3.5.3) and left on ice for 15 min, followed by sonification (four times, 5 min). Cell debris and 
DNA were pelleted and removed by centrifugation (10 min, 20000 x, 4 °C). The Pierce™ 
BCA Protein Assay Kit (23225, Thermofisher) was used to measure the total protein 
concentration of the lysate (absorption at 562nm). 40 µg per lane were separated by 
reducing SDS-PAGE and transferred to a polyvinylidene difluoride (PVDF) membrane. AAT 
was detected using a human AAT specific monoclonal antibody from a rat hybridoma (13C7, 
1:10 in PBS-T and 5 % milk, Götzfried et al., unpublished) and peroxidase-conjugated goat 
rat-specific IgG+IgM antibodies 1:10,000 (Jackson Immuno Research Laboratories). 
 Lung tissue preparation for staining of lung sections 3.7.5
Left mouse lungs were inflated with 4% PFA through an intratracheal cannula at the time of 
sacrifice, the trachea was ligated, and the lungs were fixed in 4% PFA, at 4°C overnight, and 
transferred to 70% ethanol before paraffin-embedding. The grafts were subsequently 
embedded in agarose, and cut into 3 pieces, and then separated 3 mm from each other. The 
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pieces were embedded in paraffin, and then sliced into 3 µm-thin sections with a microtome 
(Hyrax M55, Zeiss). 
 Hematoxylin and eosin staining of lung tissue sections 3.7.6
Sections were placed in a 65°C oven for 20 minutes to melt the paraffin for deparaffinization. 
Then they were transferred sequentially to 100% xylene, 100%, 90%, 80% and 70% ethanol, 
and rinsed in tap water for 5 min, followed by distilled water. First, sections were stained with 
Hematoxylin (Hematoxylin solution, GHS-232, Sigma Aldrich) for 6 min, rinsed in distilled 
water, and tap water for 15 min, followed by distilled water. Then they were stained with 
eosin for 10 min and washed in tap water for 5 min. Subsequently, sections were dehydrated 
with ethanol 100% and xylene, and mounted with glue (Entellan, Merck). For visualization the 
slides were were scanned with Myrax Desk.  
 Statistics (AAT in lung transplantation) 3.8
All results are reported as mean ± SEM. A Mann-Whitney U-test was performed using 
GraphPad Prism version 5.00 for Windows, GraphPad Software, and www.graphpad.com.  
P-values of less than or equal to 0.05 were considered significant. 
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4. More than just a pseudogene: serpina2 in the epididymis 
 Serpina2 - Introduction  4.1
 Serpina2 – a clade A serpin very similar to serpina1 (alpha-1-antitrypsin) 4.1.1
A large set of extracellular serpins prevent organ damage by inhibiting excessive proteases 
in inflammatory diseases. One poorly characterized member of this family is serpina2, which 
was originally annotated and regarded as a pseudogene. 
By definition, pseudogenes are DNA segments, which are composed like a gene, but they do 
not function as template for a functional protein30,31. A gene without function is not exposed to 
selection pressure and usually gains mutations over time. However, serpina2 is widely 
conserved, which implies that it is under natural selection pressure like a functional gene. In 
more recent studies it has been shown that some declared pseudogenes do have functions, 
after all, and that the boundary between ‘living’ and ‘dead’ genes is more ambiguous than 
initially assumed32. While several pseudogenes are definitively ‘dying’ and non-functional, 
many cases have been reported, in which the RNAs of declared pseudogenes are 
transcribed and processed to interfere with paralogous genes33,34.  
Originally serpina2 was declared to be a polymorphic pseudogene, due to a missing 
promotor region and an alteration in the start codon, in which ATG was mutated to ATA. So 
far, two major null allele variants of serpina2 are known: A 2 kb deletion affecting exon IV 
and part of exon V, and a frameshift mutation (fs108) in exon II, which leads to a premature 
stop codon35. An analysis of the 1000 Genomes Project data 
(http://www.internationalgenome.org/) performed by our collaboration partner Dr. Susana 
Seixas revealed that the fs108 mutation is most frequent in the South and Middle American 
population, but also occurs in the Middle East region and to a much lower extent in Europe. 
The deletion allele is most common in the African population, but can also be found in 
Europe (Figure 4.1). 
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Figure 4.1 Distribution of the two non-functional alleles of serpina2 (Seixas et al., 
unpublished).  
 
There are several mechanisms of how pseudogenes can be generated. One of them is the 
phenomenon of gene duplication caused by homologous recombination. Subsequently, the 
new gene can acquire mutations that lead to the exaptation of novel functions or they are on 
the path towards loss of function of the original gene and removal from the genome. Gene 
duplication is thought to be the most important driving force in evolution, since it represents 
the starting point of evolutionary innovation36. Extensive nucleotide sequence homology with 
the AAT gene suggests that serpina2 arose from a recent gene duplication event occurring 
about 90 million years ago37. Serpina2 is closely linked and highly homologues to alpha-1-
antitrypsin (serpina1), however, extremely polymorphic in human populations. Both genes 
are found next to the other nine clade A serpins on chromosome 14, and serpina2 is located 
within 12 kb downstream of the authentic human alpha-1-antitrypsin gene (Figure 4.2).  
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Figure 4.2 Organization of clade A serpins on chromosome 14q32.1. (KAL: kallikrein-like 
inhibitor, data was derived from the publicly available human genome database, 
http://www.ensembl.org/) 
 
Serpina1 and serpina2 share a protein sequence identity of 60.3% (254/421 aa), and a 
nucleotide sequence similarity of 73.2% (308/421 aa). There are only 1% gaps (4/421 aa) 
within the sequence. Though interestingly, the active sites of the proteins are quite divergent, 
which implies altered substrate specificity (marked in turquoise in Figure 4.3). Interestingly, 
serpina2 is the only known serpin carrying a tryptophan (W) residue in P1 position.  
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Serpina1           1 MPSSVSWGILLLAGLCCLVPVSLAEDPQGDAAQKTDTSHHDQ---DHPTF     47 
                     ||.|||||:|||||||||||.||.||||||||||||||||||   :.... 
Serpina2           1 MPFSVSWGVLLLAGLCCLVPSSLVEDPQGDAAQKTDTSHHDQGDWEDLAC     50 
 
Serpina1          48 NKITPNLAEFAFSLYRQLAHQSNSTNIFFSPVSIATAFAMLSLGTKADTH     97 
                     .||:.|:.:.||.||:......|. ::..:|.|:|.||.||||||||||. 
Serpina2          51 QKISYNVTDLAFDLYKSWLIYHNQ-HVLVTPTSVAMAFRMLSLGTKADTR     99 
 
Serpina1          98 DEILEGLNFNLTEIPEAQIHEGFQELLRTLNQPDSQLQLTTGNGLFLSEG    147 
                     .|||||||.||||.|||:|||.||::|:.|::||::||||||:.||:::. 
Serpina2         100 TEILEGLNVNLTETPEAKIHECFQQVLQALSRPDTRLQLTTGSSLFVNKS    149 
 
Serpina1         148 LKLVDKFLEDVKKLYHSEAFTVNFGDTEEAKKQINDYVEKGTQGKIVDLV    197 
                     :||||.||||.||||||||.::||.||||||:|||:||||.|..|:|||| 
Serpina2         150 MKLVDTFLEDTKKLYHSEASSINFRDTEEAKEQINNYVEKRTGRKVVDLV    199 
 
Serpina1         198 KELDRDTVFALVNYIFFKGKWERPFEVKDTEEEDFHVDQVTTVKVPMMKR    247 
                     |.|.:||..|||:||.|.|||:..|:.:....|.||||..|.::|||:.. 
Serpina2         200 KHLKKDTSLALVDYISFHGKWKDKFKAERIMVEGFHVDDKTIIRVPMINH    249 
 
Serpina1         248 LGMFNIQHCKKLSSWVLLMKYLGNATAIFFLPDEGKLQHLENELTHDIIT    297 
                     ||.|:|...::||||||...|:|||||.|.|||..|:..||.:||:..:. 
Serpina2         250 LGRFDIHRDRELSSWVLAQHYVGNATAFFILPDPKKMWQLEEKLTYSHLE    299 
 
Serpina1         298 KFLENEDRRSASLHLPKLSITGTYDLKSVLGQLGITKVFSNGADLSGVTE    347 
                     ......|.||.:||.|||||:|||.||.|...|||||:|||.||||||:: 
Serpina2         300 NIQRAFDIRSINLHFPKLSISGTYKLKRVPRNLGITKIFSNEADLSGVSQ    349 
 
Serpina1         348 EAPLKLSKAVHKAVLTIDEKGTEAAGAMFLEAIPMSIPPEVKFNKPFVFL    397 
                     |||||||||||.||||||||||||.||..||....|....|.||:||:.: 
Serpina2         350 EAPLKLSKAVHVAVLTIDEKGTEATGAPHLEEKAWSKYQTVMFNRPFLVI    399 
 
Serpina1         398 MIEQNTKSPLFMGKVVNPTQK    418  
                     :.|..|..|||:||||||||| 
Serpina2         400 IKEYITNFPLFIGKVVNPTQK    420 
 
Figure 4.3 Comparison of serpina1 (AAT) and serpina2 sequence homology. Signal 
peptides are marked in grey, and the reactive center loop sequences are marked in yellow 
(P4 – P4’). Pairwise sequence alignment was carried out using the EMBOSS Needle tool 
(http://www.ebi.ac.uk/Tools/psa/emboss_needle/). Protein sequences were obtained from the 
Uniprot website (http://www.uniprot.org, serpina1 - P01009 (A1AT_HUMAN) , serpina2 - 
P20848 (A1ATR_HUMAN)). 
 
The first literature specifically mentioning serpina2 was published in the 80’s. Serpina2, or 
alpha-1-antitrypsin-related gene (ATR), was suggested as a marker for prenatal diagnosis of 
AAT deficiency in 1987 (Lancet)38. One year later another study investigated the expression 
of serpina2 using a RNA protection assay against human RNA (liver, lung, spleen, skeletal 
muscle and brain) and concluded that it seemed to be a pseudogene39. However, another 
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study suggested that it might not be a classical pseudogene due to the fact that all RNA 
splice sites are conserved and the lack of internal termination codons in the exonic regions40. 
Twenty years later a research group in Portugal became interested in serpina2 and proposed 
in a genetic analysis that it is in the ongoing process of becoming a pseudogene but could 
encode a functional serpin and currently be expressed in some humans35. Additionally, they 
found that serpina2 is completely deleted in chimpanzees, but present in most great apes, 
and that serpina2 mRNA might be differentially expressed in testes and leukocytes. In a 
second publication they propose that serpina2 is an intracellular glycoprotein located in the 
endoplasmic reticulum, and that it is not degraded by the proteasome through unfolded 
protein response and therefore seems to be folding correctly. They suggest that serpina2 is a 
chymotrypsin-like protease inhibitor, because it was shown in in vitro studies that the M358W 
substitution in the RCL of AAT, which is also present in serpina2, changes the affinity of the 
inhibitor towards chymotrypsin41. Furthermore, they show that based on mRNA detection 
serpina2 is expressed in several human tissues42. 
 Hints for serpina2 expression in databases 4.1.2
Until recently, serpina2 was regarded as a pseudogene. However, there is evidence in 
several databases for the expression of serpina2.  
GTEx (https://www.gtexportal.org/ home/gene/SERPINA2) detects a signal for serpina2 gene 
expression in whole blood, and to a lower extent in the kidney, but not in testis and many 
other organs. In the EMBL-EBI gene expression atlas serpina2 is found in testis 
(http://www.ebi.ac.uk/gxa/genes/ENSG00000258597?bs=%7B%22homo%20sapiens%22%3
A%5B%22ORGANISM_PART%22%5D%7D#baseline). 
There are 67 reports for serpina2 protein identification in the Pride Archive 
(http://www.ebi.ac.uk/pride/archive/simpleSearch?q=P20848&show=10&page=4&sort=score
&order=ddes). Among them are several human plasma proteome analyses. 
In the proteomics database (https://www.proteomicsdb.org/proteomicsdb/#human/ 
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proteinDetails/53815/expression) serpina2 was found in the kidney and platelets. Six unique 
peptides were identified, with sequence coverage of 20.24%.  
To sum it up, there are multiple hints for serpina2 expression at the mRNA and protein level. 
Most of these refer to testis and blood, in particular to platelets. 
 Objectives 4.1.3
In previous work the tissue distribution and protease inhibiting function of serpina2 remained 
unclear as appropriate analytical tools were not available. The goal of this study was to 
develop such tools and determine the potential role of serpina2.  
We hypothesized that serpina2, being very homologous to alpha-1-antitrypsin, could have a 
similar role as genetic modifier of inflammatory diseases. 
So far, only polyclonal serpina2 antibodies (Santa Cruz) were available. Therefore, we 
recombinantly produced the protein for analysis and monoclonal antibodies to it for detection. 
With these new antibodies we explored protein expression in human tissue positive for 
serpina2 mRNA. In addition, we verified the expression of serpina2 with mass spectrometry 
methods to make a clear statement whether serpina2 exists as a protein. Furthermore, we 
designed experiments to analyze the functional properties of the putative protease inhibitor. 
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 Serpina2 – Results 4.2
 Serpina2 mRNA expression 4.2.1
In June 2013 it was published, that serpina2 is expressed at the mRNA level in several 
healthy human tissues including lung, liver, leukocytes and testes42. However, we discovered 
that forward and reverse primers located on the same exon and not spaced from one another 
by an intron, were used for the underlying experiment. This does not exclude the 
amplification of contaminating genomic DNA in a cDNA preparation and can lead to false 
positive results. To reexamine mRNA expression we tested a cDNA panel of 46 healthy 
human tissues, a panel of 24 different brain tissues and a megakaryocytic cell line (MEG-01). 
We found that serpina2 was exclusively expressed in the epididymis (Figure 4.4), all other 
tissues and the megakaryocytic cell line were tested negative.  
 
Figure 4.4 mRNA expression of serpina2 in 46 human tissues. (a) Quantitative RT-PCR 
analysis of a cDNA panel from human healthy organs. Transcript levels of serpina2 are 
shown relative to the expression in the epididymis. Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was used as endogenous control and data are based on three 
independent experiments (n=3, ±SD) (b) Amplified cDNA products were analyzed on an 
agarose gel to verify qPCR data. 
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  Expression and purification of recombinant serpina2 4.2.2
In order to study serpina2, our goal was to produce enough pure recombinant protein for the 
production of monoclonal antibodies, crystallization and biochemical assays. 
4.2.2.1 Expression of serpina2 in HEK 293 cells 
When HEK 293 cells were transfected with serpina2 plasmid and incubated for 4 days we 
observed that the vast majority of the plasmid remained intracellular and only small amounts 
could be detected in the supernatant. Therefore, we decided to purify the protein from total 
cell lysates under denaturing conditions in 8 M Urea (Figure 4.5). This technique allowed us 
to purify approximately 0.5 mg per 10 ml cell suspension. We used the early eluting fraction 
of serpina2 (E1) for the production of monoclonal antibodies.  
 
 
Figure 4.5 Expression of serpina2 in HEK 293 cells. Coomassie stained gel showing the 
purification of serpina2 under denaturing conditions (8 M Urea). The arrow points to the 
serpina2 band in the elution fraction. The supernatant (pH 7.4) was loaded onto a Ni-NTA 
column, washed at pH 5.3, and eluted at pH 4.5. (SN = supernatant, FT = flow through, W = 
wash, E1 - 4 = elution 1 - 4) 
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4.2.2.2 Expression of serpina2 in Schneider 2 cells 
Schneider 2 (S2) cells were transfected with a pIEx-serpina2 plasmid by our collaboration 
partner Prof. Dr. Wurm (Laboratory of Cellular Biotechnology, Institute of Bioengineering, 
École Polytechnique Fédérale de Lausanne, Switzerland), who sent us the supernatant. We 
used a Ni-NTA column to purify serpina2 under native conditions by liquid chromatography, 
followed by a second step of affinity purification using immobilized anti-His monoclonal 
antibody (Figure 4.6). However, with this technique we could generate only small amounts of 
recombinant serpina2.  
 
 
Figure 4.6 Expression of serpina2 in S2 cells. Silver stained gel showing the 
purification of serpina2 under native conditions. The arrow points to the serpina2 band in 
the elution fraction. (SN = supernatant, FT = flow through, W = wash, E1 = elution 1, E2 = 
elution 2) 
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4.2.2.3 Expression of serpina2 in E. coli 
We also tried to express and purify serpina2 in the E. coli strain BL21. Again, after 
purification with a Ni-NTA column and anti-His immunoaffinity resin, we were able to obtain 
small amounts of the soluble protein (Figure 4.7).  
 
 
Figure 4.7 Expression of serpina2 in BL21 E.coli. Silver stained gel showing the 
purification of serpina2 under native conditions. The arrow points to the serpina2 band in the 
elution fraction. (SN = supernatant, FT = flow through, W = wash, E1 - 4 = elution 1 - 4) 
 
 
With the help of our cooperation partner Jim Huntington (Cambridge Institute for Medical 
Research, University of Cambridge) and his postdoc Stéphanie Polderdijk, who are leading 
experts in the purification and crystallization of serpins, we tried to express serpina2 in 
different E.coli strains (BL21(DE3), SHuffle® Express, Rosetta™ 2(DE3)pLysS) and the 
plasmids pET24c_serpina2_His, pET28_His_SUMO_serpina2, and 
PQEwa_His_TEV_serpina2. We managed to produce several milligrams of 
His_SUMO_serpina2 by refolding the inclusion body material from BL21(DE3) cells 
transformed with the pET28_His_SUMO_serpina2 plasmid in Pipes buffer. However, when 
we cleaved off the SUMO-tag with the Sumo3 protease the protein precipitated and could not 
be used in further experiments. 
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 Generation of several monoclonal antibodies against serpina2 4.2.3
We were able to produce enough serpina2 protein in HEK 293 cells under denaturing 
conditions (8 M Urea) to immunize one rat for the production of monoclonal antibodies 
against serpina2. Hybridoma supernatants were generated in cooperation with Dr. Elisabeth 
Kremmer (Helmholtz Center Munich). From a large collection (119) of rat monoclonal 
antibodies we selected the most sensitive and specific antibodies against serpina2, that did 
not cross-react with AAT (serpina1). All hybridoma supernatants containing monoclonal 
antibodies were tested for their binding to native and denatured serpina2, as well as native 
and denatured AAT in an ELISA and by Western blotting (Figure 4.8). To make sure that a 
positive signal was not generated by a contaminating protein of HEK 293 cells, which was 
contained in our preparation of the immunogen, we secured with serpina2 purified from E. 
coli. Out of the 119 supernatants, 7 reacted only with native AAT, 3 reacted with both, native 
and denatured AAT and 17 antibodies reacted only with native and denatured serpina2 
(results of all 119 hybridoma supernatants are shown in Appendix 9.2). One antibody (mAb 
104) gave a particularly strong signal with both, AAT and serpina2 (native and denatured) 
and was used as a control in the test experiments. We picked five serpina2 specific 
antibodies yielding the highest signal in the ELISA for a large scale production of antibodies 
and used them for further experiments.  
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Figure 4.8 Selection of the most specific and sensitive monoclonal antibodies against 
serpina2. (a) ELISA showing the reactivity of several antibodies with either denatured or 
native AAT or serpina2. The recombinant proteins were coated, then hybridoma supernatant 
was added and the ELISA was developed using a HRP conjugated anti-rat secondary 
antibody and ABTS substrate. Absorbance was measured at 405 nm (n = 3, ± SD).  
(b) Western blot analysis of selected antibodies showing a strong reaction with serpina2 but 
not AAT, except for mAb 104, which strongly reacts with both proteins.  
 Serpina2 genotyping of human samples 4.2.4
We developed a genotyping strategy to detect the two known null alleles in human DNA 
samples to search for serpina2 null individuals. After isolation of DNA from whole blood or 
epididymis tissue and PCR amplification of serpina2 (primer pair DJ3754/3751), we used the 
restriction enzymes Bse LI to detect the frameshift 108 mutation (fs108) and BsmI for 
detection of the start codon deletion. We found that out of 66 tested individuals, 11 (16.67%) 
carried the fs108 mutation, and 27 (40.91%) the mutation of the start codon (ATG -> ATA). 
Only one individual, P-2107, carried both the fs108 and the start codon deletion allele, and 
represents therefore a natural serpina2 deficient individual. Data is summarized in 
Figure 4.9. 
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Figure 4.9 Genotyping of serpina2 deletion alleles in human samples. (a) DNA gel 
showing the PCR products with primer pair DJ3754/3751 at the top, followed by the PCR 
product digested with Bse LI or Bsm I.(Epi1-9: DNA extracted from epididymis tissue donor 
1-9; orange boxes describe the expected length of the fragments in bp after digestion)  
(b) Summary of all genotyped human DNA samples. Individual P-2107 carries both 
mutations and is therefore a serpina2 null individual. 
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 Serpina2 protein expression in human tissue samples 4.2.5
We found serpina2 mRNA exclusively in the epididymis. Therefore, we tested whether 
serpina2 is expressed at the protein level by Western blot. Epididymis donor tissue from 
male-to-female transsexuals (n = 9) was kindly provided by Dr. med. Matthias Trottmann 
(Funktionsoberarzt, Urologischen Klinik Großhadern, LMU Klinikum der Universität 
München). The age range of these donors was 26 – 52 years, and each patient received 
estradiol treatment for up to six years before patient samples were collected post-
orchiectomy43. 
As shown in Figure 4.9 all nine epididymis donors carry at least one functional serpina2 allele 
and were therefore expected to express the protein. With our monoclonal antibodies we were 
able to detect serpina2 in epididymal tissue lysates (Figure 4.10). Both, serpina2 mAb 75 
and mAb 80 detected a similar signal pattern. ß-actin was used as an internal loading 
control. Serpina2 was detected in all nine epididymis protein lysates from individual donors.  
 
 
Figure 4.10 Serpina2 protein was detected in epididymal tissue lysates. Western blot 
analysis using mAb 80 and secondary HRP-conjugated anti-rat AB. 
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Additionally, we stained paraffin embedded epididymis tissue sections to find out more about 
the tissue distribution of serpina2 (Figure 4.11). On some tissue slices the efferent ductuli, 
which connect the rete testis with the caput epididymis, were visible. Granula on the apical 
pole of (ciliated) epithelial cells in the efferent ductuli stained positive for serpina2. While we 
detected a very specific staining in the ductuli efferenti, the signal in the epididymis ducts 
varied much more. In one donor we detected a signal in smooth muscle cells and in another 
one in the basal nuclei of the epithelial cells.  
We were curious, whether the potentially secreted serpina2 can be found in seminal plasma 
or semen itself. We performed Western blots using samples kindly provided and genetically 
analyzed by Susana Seixas using our mAb 75. We tested semen and seminal fluid of five 
individuals carrying at least one functional serpina2 allele and one individual with two 
deletion alleles, and no signal was detected. 
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Figure 4.11 Serpina2 staining of human efferent ductules and epididymis using anti-
serpina2 mAb 75. (a) Negative control (b) Serpina2 was detected in granula on the apical 
pole of (ciliated) epithelial cells in the efferent ductules of the epididymis. (c) and (d) show a 
magnification of serpina2 staining of the efferent ductules. Serpina2 was also detected in the 
epididymis of two different donors: (e) smooth muscle cells and (f) basal nuclei of the 
epithelial cells. (Scale bars, a,b and e,f 50 µM, c and d 20 µM). 
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 Serpina2 protein expression in different blood components 4.2.6
To identify serpina2 protein in cell populations and plasma of human blood we did Western 
blot experiments using our mAb 75 and mAb 80, and the commercially available polyclonal 
peptide antibody from Santa Cruz.  
We analyzed eight different plasma samples, one of them (P2107) carried an allele for the 
frameshift mutation as well as for the start codon deletion, and is therefore used as negative 
control in a Western Blot experiment (Figure 4.12 a). For all plasma samples from donors 
carrying at least one functional serpina2 allele we detected a band at 75 kDa, but the lower 
band at approximately 47 kDa is not visible in the P2107 (null allele) sample, which strongly 
suggests that this lower is a specific signal for serpina2. In Figure 4.12 b we analyzed 50 µg 
of MEG-01 (a megakaryocytic cell line) whole cell lysate, and found that only the lower band 
(47 kDa) is visible, however we were not able to detect serpina2 in a qPCR experiment with 
MEG-01 cDNA.  
Additionally we analyzed human platelet lysate (HPL) with two of our serpina2 monoclonal 
antibodies (Figure 4.12 c and d) and compared it to the signal in plasma and serum. We 
again detected two different bands (80 and 47 kDa), the lower band was even stronger in 
HPL. Interestingly, the 47 kDa signal in HPL could also be detected with a polyclonal peptide 
antibody G12 (Santa Cruz) (Figure 4.12 e). The most dominant band in these samples are 
visible in the Coomassie stained gel, but it can be excluded that they are responsible for the 
signals in the Western blot, otherwise they should be visible in all lanes.  
An ortholog of serpina2 can be found in most great apes, but not in bonobos or 
chimpanzees35. Serum samples of several great apes, including the two species deficient for 
serpina2, were kindly provided by Dr. Andreas Bernhard (Zoo veterinarian, Zoo Leipzig, 
Germany) and our analysis revealed that our mAbs seem to react unspecifically. Bonobo and 
chimpanzee serum was supposed to serve as negative control. However, we detected a 47 
kDa band in their plasma samples as we did in gorilla, orang-utan, sacred baboon and 
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rhesus macaque. We tested the great apes sera with two different monoclonal antibodies 
and detected a signal with both of them (Figure 4.12 f and g). 
Since it was reported, that serpina2 might be expressed in leukocytes (staining with 
polyclonal serpina2 Santa Cruz antibody K12)42, we isolated PMNs and PBMCs from whole 
human blood of several donors and found that there was no protein band detectable in total 
cell lysates.  
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Figure 4.12 Western blot analysis of serpina2 in human blood. (a) Western Blot of eight 
different plasma samples, P2107 is a serpina2 null individual using mAb 75. (b) MEG-01 cell 
line lysate was analyzed and compared to a plasma sample using mAb 75.(c-e) Western blot 
of human platelet lysate (HPL), plasma and serum using three different serpina2 antibodies: 
(c) Serpina2 mAb 80, (d) Serpina2 mAb 75 and (e) Polyclonal peptide antibody (Santa Cruz), 
and secondary HRP-conjugated polyclonal anti-rat Ab. The gels on the bottom represent the 
Coomassie stained gels after Western blot transfer. (f and g) Serum samples of six great 
apes were analyzed with mAb 75 (f) and mAb80 (g); bonobo and chimpanzee (red) lost the 
serpina2 gene. For all blots we used a HRP-conjugated anti-rat secondary Ab and 
deglycosylated (PNGase F) serpina2 derived from S2 cells served as positive control. 
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Several plasma samples (also kindly provided by Susana Seixas, Portugal) were analyzed in 
a sandwich ELISA using two different mAb against serpina2 detecting different epitopes for 
capture and detection (Figure 4.13 a). As anticipated the P2107 (serpina2 deletion, see 
Figure 4.9, and no signal in Western blot, see figure 4.12) sample was negative, whereas we 
detected a very high signal for P1713 and P1847 (Figure 4.13 b). 
 
 
Figure 4.13 Sandwich ELISA to measure serpina2 in plasma. (a) Experimental setup: 
Anit-serpina2 mAb 75 was coated, then incubated with available plasma samples. For 
detection of potentially bound serpina2 biotinylated mAb 80, Avidin-HRP and TMB substrate 
were added. (b) Plasma sample P1713 and P1847 gave very strong signals in the sandwich 
ELISA. Serpina2 from S2 cells was used as a positive control. Absorbance at λ=370 nm was 
measured after 15 min incubation. 
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 Glycosylation of recombinant and natural serpina2 4.2.7
To find out more about the glycosylation state of recombinantly expressed and natural 
serpina2 in epididymis tissue lysate and HPL, we performed deglycosylation experiments 
using PNGase F and Endo H (Endo-ß-N-acetylglucosaminidase H). While PNGase F is able 
to cleave off almost all N-linked glycans, Endo H is unable to cleave N-linked complex type 
glycans. Serpina2 contains four theoretical N-linked glycosylation sites. We could show that 
serpina2, overexpressed in HEK 293 cells, can be deglycosylated by PNGase F and Endo H 
meaning that it never entered the Golgi apparatus and no complex sugars were attached to 
the protein. The Western blot signal in cell culture supernatants is most likely due to proteins 
released by dead cells (Figure 4.14 a). On the contrary, serpina2 in human epididymis lysate 
can be deglycosylated with PNGase F but not Endo H treatment. A signal for natural 
glycosylated serpina2 can be detected at about 50 kDa, whereas a deglycosylated sample 
appears at about 47 kDa. Since Endo H is unable to deglycosylate the protein it must have 
passed the Golgi apparatus and contained complex sugars. Also a higher band of about 80 
kDa was detected in Western blot; this signal reacts in the same manner to deglycosylation 
as the lower serpina2 band. The higher band could represent a serpina2-protease-complex 
or our antibody cross-reacts with another protein (Figure 4.14 b). In Figure 4.14 c we 
deglycosylated HPL and compared it to deglycosylated recombinant serpina2 (S2). For HPL 
we only detect a slight shift of the 47 kDa band when treated with PNGase F, and the higher 
band in HPL follows the same pattern as the 80 kDa band in the epididymis lysates. 
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Figure 4.14 Deglycosylation of recombinant and natural serpina2. (a) Western blot 
analysis of cell lysate and cell culture supernatant of HEK 293 cells transfected with serpina2 
plasmids. (b) Western Blot analysis of human epididymis lysate from three different donors. 
(c) Western Blot analysis of human platelet lysate and recombinant serpina2 derived from S2 
cells. All samples were treated with PNGase F and Endo H to monitor protein trafficking. 
Western blots analyses were carried out using mAb 75 and secondary HRP-conjugated 
polyclonal anti-rat Ab. 
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 Mass spectrometry analysis of human tissue lysates 4.2.8
Particularly, as we also found a few hints for serpina2 expression in whole blood and 
platelets in databases, we tried to verify these results and also our own Western blot results 
for epididymis tissue lysate pointing to serpina2 expression.  
In a mass spectrometry analysis of samples that we immunoprecipitated with our newly 
established monoclonal antibodies (SA2 mAb 80 and 75, see Figure 4.8), we found up to two 
unique peptides in human platelet lysate (pool originated from more than 100 donors), in the 
serum of one man, and up to six unique peptides in epididymis total cell lysate from two 
individual donors (p=0.01). 
Interestingly, when we tried to analyze total cell lysates (DDA and DIA mode, see 3.4.8.3) 
without immunoprecipitation we were not able to identify any peptides. 
 Finding potential target proteases of serpina2 4.2.9
We designed and evaluated FRET substrates that mimic the reactive center loop of serpina2 
with the goal to find target proteases of potential inhibitor. Serpins are pseudo-substrates 
(decoy substrates) which entrap proteases by virtue of an exposed reactive center loop. 
Once the peptide loop is bound to the target protease, the serpin undergoes a drastic 
conformational change causing an irreversible inhibition of the protease.  
One substrate, designed to equal the reactive center loop of serpina2 completely, was best 
cleaved by chymotrypsin, but also cathepsin G (CTSG), neutrophil elastase (NE), proteinase 
3 (PR3), and trypsin (TR). The second substrate also mimicked the reactive center loop, but 
contained two additional prolines, which prevent cleavage before and after this position. This 
substrate was only cleaved by CHTR, and not by any other tested protease (Figure 4.15). 
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Figure 4.15 Specificity of FRET substrates mimicking the RCL of serpina2 towards 
serine proteases, trypsin and chymotrypsin. (a) Table showing the reactive center loop 
sequence of serpina1 and serpina2 (P15 – P4’). (b) Cleavage of a FRET substrate (5-
TAMRA-EKAWSKYQ-Dap(CF)) that exactly mimics the RCL of serpina2. (c) Cleavage of a 
FRET substrate with two proline substitutions (5-TAMRA-EKPWSKPQ-Dap(CF)) that is very 
similar to the RCL of serpina2. Fluorescent signals were obtained at λEx = 485 nm and λEm 
= 520 nm. Data represent the mean of three independent experiments (n=3, ±SD). 
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Moreover, we investigated whether a serpina1 chimera, carrying the reactive center loop of 
serpina2 can be cleaved by proteases. For this purpose we cloned the reactive center loop of 
serpina2 into the AAT sequence (pTT5 vector), produced the serpina1 chimera in HEK 293 
cells and purified it by Ni-NTA affinity chromatography. After incubation with several 
proteases we found, that the protein was cleaved by cathepsin G, chymotrypsin and trypsin 
suggesting again that chymotrypsin-like proteases are putative targets of serpina2. However, 
we observed that the serpina1 chimera did not form covalent complexes with any of the 
tested proteases. We also tested additional proteases in silver gels and found that cathepsin 
L and to a lesser extent cathepsin B were able to cleave the serpina1 chimera (no 
complexes), but not kallikrein 3, cathepsin C and mast cell chymase. In activity assays the 
most promising protease candidates, chymotrypsin and trypsin, were not inhibited when 
incubated with the serpina2 chimera.  
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Figure 4.16 Protease cleavage of a serpina1 chimera carrying the reactive center loop 
of serpina2. (a) Table showing the reactive center loop sequence of serpina1, serpina2 and 
the serpina1 chimera (P15 – P4’).(b) Serpina1 chimera incubated with several proteases (10 
min, 37 °C) on a silver stained SDS-PAGE gel. 
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 Serpina2 – Discussion 4.3
 Serpina2 tends to precipitate when recombinantly expressed 4.3.1
We managed to purify enough serpina2 expressed in HEK 293 cells under denaturing 
conditions to establish rat monoclonal antibodies. And we obtained small amounts of soluble 
serpina2 from S2 cells and E. coli cells.  
In general, serpina2 folds poorly when overexpressed and forms intracellular aggregates. 
The karyotype of HEK293 cells is very complex and shows many abnormalities. It contains 
two or more copies of each chromosome with a chromosome number of 64. One variation is 
the presence of three copies of the X chromosome and it lacks any trace of a Y 
chromosome44. This suggests that the source fetus was female and we cannot exclude that 
the serpina2 gene was epigenetically silenced or affected in another way by this cell line, 
since it seems to be specific for male individuals. 
We were able to produce several milligrams of SUMO-tagged serpina2 in E.coli BL21 cells 
with the pET24c_His_SUMO_serpina2 plasmid. Small ubiquitin-related modifier (SUMO) 
fusions are known to enhance the solubility of expressed fusion proteins45. To prevent 
precipitation of the protein, we chose a refold buffer containing Pipes, pH 6.5, to make sure 
that neither His_SUMO_serpina2 (pI 7.07) nor serpina2 with cleaved His-SUMO tag (pI 8.82) 
are in a solution at a pH that corresponds to their isoelectric point, because at this point a 
protein exists as an ampholyte and shows the least solubility. Nevertheless, cleaving off the 
SUMO-tag resulted in complete precipitation of the protein, which is another indication, that 
serpina2 tends to form aggregates very strongly.  
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 Serpina2 mRNA and protein expression in human tissues 4.3.2
In our studies we could reveal, that serpina2 mRNA transcripts can only be found in the 
epididymis. Our results disprove the previously published data on serpina242, because of 
inappropriate primers used in these PCR experiments.  
Our genetic analysis revealed that the ortholog of serpina2 in the mouse is called serpina1f 
(Figure 4.17). 
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Figure 4.17 Phylogenetic tree showing the relationship of human serpina2 and murine 
serpina1f. The evolutionary history was inferred by using the Maximum Likelihood method 
based on the Jukes-Cantor model. The tree with the highest log likelihood (-8636,11) is 
shown. The percentage of trees in which the associated taxa clustered together is shown 
next to the branches. Initial tree(s) for the heuristic search were obtained automatically by 
applying Neighbor-Join and BioNJ algorithms to a matrix of pairwise distances estimated 
using the Maximum Composite Likelihood (MCL) approach, and then selecting the topology 
with superior log likelihood value. The tree is drawn to scale, with branch lengths measured 
in the number of substitutions per site. The analysis involved 37 nucleotide sequences. 
Codon positions included were 1st+2nd+3rd+Noncoding. All positions containing gaps and 
missing data were eliminated. There were a total of 646 positions in the final dataset. 
Phylogenetic and molecular evolutionary analyses were conducted using MEGA version 746. 
 
Compared to other serpin orthologs in the mouse (serpina1a –serpina1e) serpina1f shares 
little homology with the human serpina2 (38% amino acid identity)47. However, serpina1f has 
also been reported to be highly expressed in the mouse epididymis48. This data strongly 
supports our result, that serpina2 is as well predominantly expressed in this organ. 
Additionally, serpina1f mRNA expression has been shown to increase significantly around 
puberty when the testosterone level in plasma increases indicating androgen-dependence48. 
In general, human and mouse genes are highly conserved. The serpin gene families in both 
species represent a result of multiple gene duplication events, though the murine serpin 
clusters show an even higher degree of divergence. It has been discussed, that the driving 
force behind that could be the potential exposure to a higher number of pathogen-associated 
proteases49. One could speculate that the function of serpina2 could also be associated to a 
defense mechanism against harmful proteases released by bacteria. Several examples of 
genes containing the serpin domain have been reported to play important roles in 
antimicrobial actions50-52 and the fertility process53-55. 
The epididymis is an elongated cord-like structure along the posterior border of the testis 
(Figure 4.18). Its elongated coiled duct system serves the maturation, transit, and storage of 
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spermatozoa. Prior studies reported transcriptomics data of the different regions of the 
epididymis: caput, corpus and cauda. In these studies serpina2 was not identified56. It is 
possible that serpina2 mRNA can only be found in the efferent ductules and that our 
commercial mRNA sample also contained epididymis material and efferent ductules, while in 
the published study these parts were carefully separated as they were interested in the three 
distinctive parts of the epididymis. 
 
 
Figure 4.18 Vertical section of a human testicle to show the location of the epididymis 
and the efferent ductules. The efferent ductules and the epididymis structure are depicted 
in red. Fully matured spermatozoa are transported from the testis to the epididymis and then 
the ductus deferens (vas deferens) transports sperm to the ejaculatory ducts. Our 
immunoprecipitation results demonstrate that serpina2 is most likely expressed in the 
efferent ductules (marked in dark blue).  
 
With our newly established serpina2 monoclonal antibodies we were able to detect protein in 
human tissues. The variable band intensities we detected in the Western blot experiment 
with epididymis tissue (see 4.2.5) are probably due to incomplete tissue disruption of some 
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samples, and to variation in the tissue samples themselves, the epididymis is divided in 
substructures (Caput, corpus, and cauda epididymis) that show in general different protein 
expression patterns. Since we found strong, specific protein signals in the efferent ductuli by 
immunohistochemistry, which are directly connected to the caput epididymis, tissue from this 
region is more likely to show a positive signal for serpina2 in Western blot. However, we 
have no information from which section of the epididymis the tissue was derived from. We 
also have to take into account, that the analyzed epididymis donor tissue from male-to-
female transsexuals was quite heterogeneous: patients were not equally pre-treated with 
estradiol, most of them received additional medication (Gonadotropin-releasing hormone 
analogues (GnRH), progestins, progesterone, anti-androgens), and they were different in 
age43. 
Another study using these same tissue samples revealed that long-term estradiol treatment 
significantly reduced the diameter of seminiferous tubules in the testis, it increased collagen 
synthesis in the extracellular matrix and spermatogenesis was severely impaired43. 
Therefore, no mature spermatids could be observed in the stained tissue sections and the 
limitations of our results are that the pretreatment of the male-to-female transsexuals could 
also have an effect on serpina2. We cannot formally exclude that serpina2 protein 
expression was induced by hormone treatment, and our data might not represent serpina2 
protein expression in normal testis tissue. 
We also have to take the inconsistent treatment of donors into consideration for evaluation of 
serpina2 signal on the epididymis tissue sections. We detected the strongest signal of 
serpina2 in the ductuli efferenti (Figure 4.18). In large mammals, like humans, multiple 
entries connect the rete testis and the epididymis, approximately 6 - 15 efferent ductuli 
connect the rete testis with the caput epididymis. In smaller animals, for example in rodents 
only 3 – 8 ductules merge into a single duct that enters the epididymis57. The ductuli efferenti 
are covered by a stratified epithelium consisting of highly prismatic cells often carrying motile 
cilia (kinocilia). The ciliated cells serve to stir the luminal fluids, to increase the concentration 
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of luminal sperm. The epithelium is surrounded by a band of smooth muscle cells that helps 
to propel spermatids toward the epididymis. It could be speculated that serpina2 interacts 
with a protein related to the epididymis cilia. Several serpins are known, that do not exhibit 
classical inhibitory activity, but carry out other important functions. One well known member 
of the serpin family, which acts as chaperone and is found in the endoplasmic reticulum, is 
serpinh1. It is responsible for monitoring the collagen integrity in ER\Golgi boundary58. 
Perhaps serpina2 has a chaperone-like function, which would also fit to the fact that it is 
poorly or not at all secreted. The serpina2 positive granula on the apical pole of (ciliated) 
epithelial cells could either be a result of actually expressed and correctly folded serpina2 
that has a function in sperm maturation, or the positive signal is due to aggregated serpina2 
accumulation in granula or lysosomes, straining the health of epithelial cells. However, if that 
is the case, the question remains why serpina2 is not degraded by the unfolded protein 
response or autophagy in these epithelial cells. There are various protein quality control 
pathways available by mammalian cells, but there are also cases in which protein 
degradation is circumvented and misfolded proteins are deposited inside the cells. At the 
point where cells can no longer withstand the pressure of misfolded proteins, the organism is 
usually negatively affected. It is well known, that polymerization is a consequence of some 
natural serpin mutants. The most popular example of an aggregation prone serpin is the Z-
mutant of serpina1 (introduced in 2.3 Alpha-1-antitrypsin deficiency), which is associated with 
lung emphysema and liver cirrhosis24. 
The phenomenon of disease development due to failing protein homeostasis has also been 
extensively studied in devastating neurodegenerative diseases like Alzheimer’s or 
Parkinson’s disease. The proteins that cause these diseases have a very high propensity to 
misfold or aggregate and therefore represent a potential threat for the survival of cells and 
the well-being of an organism59.  
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These examples of deposition of misfolded proteins share common features – they exhibit a 
propensity to misfold/aggregate, but are usually soluble and they seem to build up later in life 
suggesting a gradually fail with age of protein quality control pathways59. 
Just like individuals expressing the Z-mutant of serpina1, those expressing serpina2 could 
have a disadvantage due to misfolded protein in their epithelial cells of the epididymis 
presumably later in life. 
Predominantly in human platelet lysate, but also in serum and plasma we detected a positive 
signal in Western blots with our newly established serpina2 antibodies. Remarkably, in 
human platelet lysates the same band was detected by a commercially available serpina2 
peptide antibody. The serpin superfamily includes serine protease inhibitors essential for the 
cascade of blood coagulation. Therefore, it is conceivable that serpina2 could also play a role 
in fine tuning of this mechanism. We also tested sera from grate apes and detected not only 
a positive Western blot signal in the ones known to express serpina2, but also in those with 
serpina2 deletion (bonobo and chimpanzee), which were supposed to serve as negative 
control. The limitations of our study are that we cannot exclude that our antibodies cross 
react to some extent with abundant serpins existing in human samples, because this family 
shares a very similar structure. However, we ruled out their reaction with serpina1.  
Additionally, we analyzed seminal fluid by Western blotting and could not detect any signal. 
Seminal plasma is known to contain a large number of proteases and protease inhibitors, 
including many serine protease inhibitors like serpina1 or serpina560. That our antibodies do 
not cross react with any of these serpins supports the assumption that we detect a real 
positive serpina2 signal in other samples. 
Intrigued by this positive signal, in particular in human platelet lysate, we performed 
deglycosylation experiments and revealed that serpina2 overexpressed in HEK 293 cells 
does not enter the Golgi apparatus, whereas natural serpina2 could not be deglycosylated by 
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Endo H, which means that it must have been processed in the Golgi like a normally folded 
protein. 
In addition, we developed a sandwich ELISA to check whether we can detect serpina2 in 
human plasma samples. Our analysis revealed that two out of 33 samples exhibited very 
strong positive signals (P1713 and P1847), whereas the plasma sample from the serpina2 
deficient individual (P2107) was tested negative for serpina2 in Western blot (Figure 4.12). 
The positive ELISA signals again support the assumption that serpina2 is present in human 
plasma. Unfortunately, the genotype of P1713 and P1748 is unknown, however, as a next 
step we will try to verify whether serpina2 peptides can be found in those plasma samples 
after immunoprecipitation with our serpina2 mAbs.  
 Serpina2 peptides are found in blood and epididymis samples 4.3.3
The result of our mass spectrometry experiments further revealed that serpina2 might not be 
a pseudogene after all. The protein was identified in human platelet lysate, serum and the 
epididymis. It was, however, expressed at very low level, and could only be identified after 
immunoprecipitation using our newly established serpina2 mAbs.  
 Genotyping of serpina2 4.3.4
In order to find a human negative control blood sample we analyzed 66 human DNA samples 
and found that 16.67% carried the fs108 mutation, and 40.91% the start codon deletion 
mutation. Only one individual turned out to be a serpina2 null individual (P2107). In P2107 
plasma we could not detect a positive band around 47 kDa like in the other human samples, 
indicating that the western blot signal might be genuine (Figure 4.12).. 
 Chymotrypsin-like proteases could be targets of serpina2 4.3.5
CHTR was able to cleave both FRET substrates mimicking the RCL of serpina2, suggesting 
that chymotrypsin-like proteases could be potential candidates for target proteases. 
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In experiments with serpina1 chimera carrying part of the RCL of serpina2 we noticed that 
the protein did not show any signs of misfolding. Although the chimera did not form 
complexes with proteases, it was cleaved by chymotrypsin, trypsin and cathepsin G, proving 
that the loop was in principle accessible.  
Serpina2 is the only known serpin with a tryptophan in the P1 position. Interestingly, 
according to the ensemble database (serpina2, LOC103158570) the Chinese hamster also 
carries a serpina2 gene with tryptophan in P1 position, but unfortunately there is also no 
additional information on hamster serpina2.  
In search of a possible target protease of serpina2, the serine protease Prss40 attracted our 
attention. Speaking in terms of evolution, the loss of Prss40 preceded the loss or inactivation 
of serpina2. Interestingly, pseudogenes of serpina2 are found in species that lack a 
functional Prss40. In line with this observation, a functional Prss40 gene can only be found in 
species with a functional serpina2 gene. It seems quite possible that pseudogenization of the 
protease Prss40 resulted in the disappearance of the corresponding protease inhibitor. 
In 1998 Prss40 was first described as a novel serine protease in the acrosome of mouse 
sperm, where proteolytic enzymes are important for the limited hydrolysis of the zona 
pellucida. This is the barrier, which sperm cells have to traverse in order to successfully 
fertilize a mammalian egg. The Prss40 gene product is predicted to have chymotrypsin-like 
activity because it shares sequence similarities and active site features (Ser-189; 
chymotrypsinogen numbering) with chymotrypsin-like enzymes61. 
Several indications for a role of proteases and inhibitors in fertility can be found in the 
literature62,63. For example disruption of the protein C inhibitor (serpina5) results in male 
infertility in mice64. Serpina5 and serpina2 are close neighbors, located on the same 
chromosome (see Figure 4.2). Another example is Prss37, a protease that has been shown 
to be required for sperm migration. Prss37 knockout resulted in male infertility65. Moreover, it 
has been reported that chymotrypsin treatment of sperm cells improves intra-uterine 
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insemination and pregnancy rates after in vitro fertilization66-69. It is conceivable that sperm 
cells could be pretreated with Prss40 in a much more targeted manner than it is being done 
with chymotrypsin. 
To explore, whether serine protease 40 is a real target of serpina2 we aim to produce active 
recombinant Prss40 for functional analysis. This approach will provide further insight into the 
function and relevance of serpina2. 
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 Concluding remarks on serpina2 4.3.6
This work has unambiguously demonstrated that serpina2 is not a classical pseudogene but 
rather a lowly expressed gene that can be found in the epididymis at the mRNA and protein 
level. We are not completely convinced that serpina2 expressed in human blood. On the one 
hand, we were not able to find a mRNA source and we have to consider unspecific binding of 
the newly established serpina2 antibodies. On the other hand, we found a serpina2 signal 
even with the commercially available peptide antibody, too, and finding peptides in mass 
spectrometry experiments is an indication for the presence of serpina2. 
We could not conclusively characterize a possible function of serpina2, however, we 
assume, when folded correctly, it is most likely able to inhibit chymotrypsin-like proteases. 
It is conceivable that possibly misfolded or aggregated serpina2 is disadvantageous in 
humans, and that it is preferable not to have it. In this case, however, it seems odd to find an 
intact serpina2 in most primate species and it is difficult to explain why it has been kept for so 
long, and why there are not more cases of gene inactivation in other species.  
In an ongoing study we are examining blood and sperm quality of semen donors with the 
help of the Cryobank München (Viavit GmbH) to identify serpina2 deficient individuals at the 
genetic and biochemical level. We hope to find more negative control samples to verify the 
specificity of our antibodies and ideally to identify a difference of sperm quality and overall 
fertility in presence or absence of serpina2.  
In conclusion, serpina2 is not a pseudogene; it is an epididymis specific potential inhibitor of 
chymotrypsin-like proteases and may improve sperm maturation. 
For a better understanding of male fertility and reproductive success it is important to 
understand the mechanism of all ongoing protease – inhibitor interactions, and to identify 
potentially harmful proteins like serpina2. 
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5. Characterization of two common coding variants of serpina1 
(M1(V213) and M1(A213)) 
 Serpina1 coding variants- Introduction 5.1
Several major alleles of AAT (serpina1) can be found in human populations: the normal M 
alleles (M1, M2, M3, M4) and the rare S and Z variants. The M alleles result in normal levels 
of AAT, the S allele in reduced levels and the Z variant leads to very low levels of AAT in 
blood. The M allele is considered as normal type resulting in a normal phenotype (MM) with 
functional activity to inhibit neutrophil elastase efficiently70. In this study we investigated the 
properties of two different variations of the M1 allele: M1(V213) and M1(A213). A213 
represents the minor allele, whereas V213 is the prevailing M1 allele in Caucasians. Both 
variants have been shown to be functionally equivalent plasma isoforms leading to very 
similar plasma levels of AAT71. In order to provide evidence for the differential properties of 
the two M1 alleles the corresponding proteins were stably expressed in HEK 293 cells, 
purified and functionally characterized in a hydrogen/deuterium exchange measurement 
experiment combined with mass spectrometry. 
 Serpina1 coding variants – Results 5.2
 Expression of two AAT variants: M1(V213) and M1(A213) 5.2.1
HEK 293 cells were transfected with pTT5-hAAT_ M1V213 or pTT5-hAAT_ M1A213 plasmid 
and incubated for 4 days. The protein was very efficiently produced and secreted, and high 
amounts of the two proteins were purified by Ni-NTA chromatography (Figure 5.1 a). The 
approximately 47 kDa proteins were dialyzed in buffer containing 300 mM NaCl, 20 mM Tris, 
and 10% glycerol (pH 7.4) before they were analyzed in a hydrogen/deuterium exchange 
measurement experiment by our collaboration partner Patrick Wintrode (University of 
Maryland, School of Pharmacy)72.  
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 Hydrogen/deuterium exchange measurement 5.2.2
To find out more about the impact of the amino acid at positon 213 of the AAT molecule, the 
hydrogen/deuterium exchange rates of the M1(V213) and M1(A213) variant were 
determined. As depicted in Figure 5.1 b, the hydrogen/deuterium exchange rates between 
the two AAT variants demonstrated significant differences for multiple peptides. In general 
the alanine variant was more susceptible to deuterium uptake in several surface regions 
when compared to the valine variant. Especially the M1(A213) substitution resulted in 
significantly less rigidity of the C-terminal end of the serpins’ RCL. Additionally, the strand 
one of the C ß-sheet (s1c) and strand five of the A-sheet in the shutter region (s5A) exhibited 
a higher flexibility. In general, we can state that the AAT M1(A213) variant features increased 
dynamics. 
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Figure 5.1 Expression of M1(V213) and M1(A213) and hydrogen/deuterium exchange 
measurement. (a) Coomassie gel of AAT M1(V213) and M1(A213) protein after Ni-NTA 
purification. (b and c) Differential dynamics of hydrogen/deuterium exchange between AAT 
variant M1(A213) and M1 (V213). (b) The increasing difference in deuterium uptake across 
five time points (10 sec – 7200 sec) is compared between the two AAT variants. The results 
are mapped onto the crystal structure of AAT (PDB: 1QLP). A two- to threefold increase of 
deuterium uptake is labeled in red and a one- to twofold increase is marked in pink. For the 
grey areas there was no significant difference detected. (c) Exemplary kinetic curves for the 
hydrogen/deuterium exchange measurement. For peptide 100 – 112 there was no difference 
detected, whereas peptide 134 – 143 showed a significant difference between the two AAT 
variants at all time points (N=3). 
5.3 Serpina1 coding variants - Discussion 
80 
 
 Serpina1 coding variants - Discussion 5.3
Analyzing the two purified serpina1 variants, M1(V213) and M1(A213), in a 
hydrogen/deuterium exchange experiment revealed differences in the global flexibility of the 
two proteins. In addition, it has been shown in thermophoresis experiments that the 
M1(V213) variant interacts stronger with plasma lipoproteins72.  
In former studies performed with the two purified AAT variants in protein- and lipid-free 
solution no differences between the two proteins were detected. The microscale 
thermophoresis, which allows to measure AAT – NE interaction in complex solutions like 
plasma under equilibrium conditions, revealed that M1(V213) exhibits a lower affinity to NE 
than the M1(A213) variant. The hydrogen-deuterium exchange experiment showed that 
M1(V213) exhibited a reduced flexibility which favors the interaction with other plasma 
proteins. M1(V213) also displays higher hydrophobicity. Therefore, its interaction with plasma 
lipoproteins (HDL (high density lipoprotein), LDL (low density lipoprotein) is increased and, in 
turn, the interaction with NE is reduced. This would reduce proteolytic inactivation, and most 
likely improves its local availability by co-transport with lipoproteins. 
These findings were published together with a transethnic (Europe, Australia, South Asia), 
exome-wide association study which revealed the M1(A213) variant to be associated with 
large artery atherosclerotic stroke72. The exact mechanism by which M1(V213) reduces the 
risk for large artery stroke is not yet fully understood, however, binding to lipoproteins may 
enhance the local availability of M1(V213) in atherosclerotic plaques compared to the 
M1(A213) variant. Moreover, M1(A213) being more dynamic and flexible is more prone to 
proteolytic inactivation by other proteases.  
This study illustrates an example of a functionally relevant coding sequence variation in 
which a single-residue variation outside the inhibitory reactive center loop of the protease 
inhibitor AAT leads to an alteration that affects its overall structural flexibility and binding 
properties.  
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6. Preservation with alpha-1-antitrypsin improves primary graft 
function of murine lung transplants 
 AAT in lung transplantation - Introduction 6.1
Optimal preservation of post-ischemic graft function is essential in lung transplantation. 
When a lung is transplanted it faces two major challenges: The first one is the ischemic 
storage at 4 °C in which the lung is not supplied with blood. The second challenge is 
reperfusion, which causes lung injury when blood returns back to the grafted tissue. Both can 
contribute to primary graft dysfunction (PGD), which is defined as severe form of acute lung 
injury induced by ischemia/reperfusion and occurs within the first 72 hours after 
transplantation. PGD is the major cause of early mortality and morbidity after lung 
transplantation, it affects up to 25% of all patients73. To date there are no proven therapies 
that prevent PGD. Therefore, it is very important to find new strategies to avoid the early 
onset of inflammation in transplanted lungs.  
Additionally, primary graft dysfunction as well as vascular damage increases with prolonged 
preservation times. Therefore, storage and conservation of donated lungs in protein-free, 
dextran-containing electrolyte solutions is limited to about six hours. A more sophisticated 
preservation technique could make it possible to increase the donor pool by allowing longer 
storage times. 
In order to improve the conventional storage solution we hypothesized that proteases 
released by activated neutrophils in primary graft dysfunction can be neutralized by the 
natural protease inhibitor AAT, when added to the perfusion solution (Perfadex) during cold 
ischemic storage (Figure 6.1).  
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Figure 6.1 Composition of ordinary Perfadex and the addition of AAT. 
 
Advantageous effects of protease inhibitors, in particular of alpha-1-antitrypsin (AAT), have 
been noticed in certain models of ischemia-reperfusion injury74-77 at 37 °C75,77. These 
experimental setups, however, do not appropriately mimic the challenges of ex vivo organ 
storage in a cold cell- and protein-free electrolyte solution like Perfadex78. Positive results 
from these previous studies cannot be extrapolated to reperfusion injury after preservation of 
organs in the cold. Primarily infiltrating neutrophils79,80 and the duration of oxygen deprivation 
81,82 are responsible for the irreversible damage of the transplanted lung tissue. Since 
activated neutrophils release large amounts of serine proteases, like elastase and proteinase 
3, protease inhibitors like bovine aprotinin83,84, Lex03276,85, and AAT74,75,77,86 have been 
explored experimentally in animal models for treatment of lung transplant recipients. To 
increase the protease inhibitor concentration in the circulation, they have been administered 
intravenously or intraperitoneally in these studies21. We hypothesized that the inhibitors 
examined in these studies did not efficiently protect the transplanted graft against infiltrating 
activated neutrophils, because some applied inhibitors did not have the appropriate inhibitory 
profile, and they reached the inhibitor-depleted graft in the course of reperfusion too late. 
To initiate proof of concept experiments, we developed a new clinically appropriate lung 
preservation protocol for lung transplant patients. We used a murine orthotopic lung 
transplantation model (see Figure 6.2, established by Krupnick et al.29), and stored the lung 
graft in Perfadex containing AAT (1 mg/ml) for an extended time period of 18 hours at 4 °C.  
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Figure 6.2 Mouse model of orthotopic lung transplantation. (a) Model of a murine lung: 
the right lung consists of four lobes and the left lung only of one lobe. (b) Principle of left lung 
transplantation in the mouse: first the pulmonary artery (PA, red) is attached to the recipient, 
then the pulmonary vein (PV, blue), and finally the bronchus (Br, orange). (c) Picture of left 
donor lung attached to the recipient during surgery (taken by Natalia Smirnova). 
 
The aim of this preclinical study was to test if vascular leakage and immediate onset of 
neutrophil-mediated inflammation after reperfusion can be circumvented or soothed by 
adding AAT to the Perfadex perfusion solution during cold ischemia. Further, we wanted to 
find out whether the anticipated enhancement of lung graft function can directly be deduced 
from AAT’s protease inhibiting or from other anti-inflammatory, tissue protective or immune 
modulatory properties. Our results reveal that AAT affects neutrophil-derived elastase and 
proteinase 3 and mostly prevents immediate reperfusion damage by protease inhibition in 
the tissue of lung transplants. 
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 AAT in lung transplantation – Results 6.2
 Production of AATwt and AATmt 6.2.1
The cDNA modification of the human AATmt (A355D/I356P/P357D/M358S) was introduced 
by amplifying the cDNA of human AAT with the primer pair DJ3608/DJ360987 (see 3.1.3). 
Acc I and Abs I restriction enzymes (NEB) were used to digest the PCR product. 
Subsequently, it was cloned into the respective sites of the previously modified wild type 
pTT5_AAT plasmid. 
The AATwt (human M1(V213)) and AATmt plasmids were utilized for transient expression in 
HEK293 cells72. We successfully purified large amounts of the proteins and dialyzed them in 
Perfadex solution for later administration in the orthotopic mouse transplantation 
experiments. 
 Treating lung grafts with AAT during storage is more efficient than AAT 6.2.2
injection of transplant recipients prior to surgery 
We injected mice with 60 µg/g AAT86 and determined the AAT content in their lungs after one 
and four hours (Figure 6.3 a). We also analyzed the levels of AAT four hours after orthotopic 
lung transplantation in mice whose graft had been stored under cold ischemia conditions in 
AAT (1 mg/ml in Perfadex) by Western blotting (Figure 6.3 b). We found that the local 
deposition of AAT was much better achieved in the latter procedure, in which plasma 
proteins were absent (Figure 6.3 c). 
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Figure 6.3 Storage in AATwt containing Perfadex leads to increased AAT levels after 
reperfusion (4 h) compared to intraperitoneal AAT injection of the recipient mouse. (a) 
Experimental outline of i.p. injection of AATwt. (b) Experimental outline for storage in AATwt 
during cold ischemia (18 h, 4 °C) followed by implantation and reperfusion (4 h, 37 °C).  
(c) Western Blot analysis of total left lung tissue lysate. Lane 1: vehicle i. p. injection, lane 2: 
1 h after AATwt injection, lane3: 4 h after AATwt injection, lane 4 -7: transplanted left lungs of 
four C57BL/6J recipient mice after 4 h of reperfusion. A specific monoclonal antibody was 
used for detection of AATwt and detection of β-actin served as a loading control (see lower 
panel). 
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 Vascular integrity after cold ischemia 6.2.3
To check whether the lung vasculature is better preserved when AAT is added to the storage 
solution, we perfused lungs with Evans Blue either before or after storage of 18 hours. 
Without storage we were able remove the blue stain by flushing with PBS (Figure 6.4 a). 
After storage for 18 hours at 4°C the vasculature was damaged and we were not able to 
remove Evans Blue by flushing with PBS, irrespective of whether the graft was stored in 
Perfadex alone or in Perfadex supplemented with Albumin or AAT (Figure 6.4 b). 
 
 
 
Figure 6.4 Visualization of the loss of vascular integrity after cold ischemia. (a) Left 
mouse lung before (top) and after perfusion with Evans Blue (without storage) followed by 
perfusion with PBS (bottom). (b) Left mouse lung before (top) and after perfusion with Evans 
Blue followed by perfusion with PBS (bottom) after 18 h storage at 4 °C. The lungs were 
either stored in Perfadex alone (left), Perfadex supplemented with albumin (1 mg/ml) 
(middle), or Perfadex supplemented with AAT (1 mg/ml). (Pictures were taken by Natalia 
Smirnova.) 
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 Storage in AAT improves PGD 6.2.4
A murine orthotopic left lung transplantation model was used to assess PGD after prolonged 
cold ischemia storage of the left lung in Perfadex (Figure 6.3 b). We clearly noticed cellular 
infiltrates in the transplanted left lobe and neutrophils in the bronchoalveolar lavage fluid. 
After stopping the air and blood flow from the non-transplanted right lung by clamping the 
right bronchus, the partial oxygen pressure (pO2) in the left heart ventricle decreased 
indicating graft dysfunctions after prolonged cold ischemic storage. With the goal to improve 
preservation of the lung graft, we explored the potential beneficial effect of AAT by perfusing 
and storing the lung graft at 4 °C in Perfadex supplemented with AAT. We directly compared 
AAT with albumin at the same concentration in our mouse transplantation model (Figure 
6.5). As envisioned, we found a highly significant protective effect on graft preservation both 
at the histopathological (Figure 6.5 a) and functional level (Figure 6.5 b to e). Addition of 
AAT resulted in an almost 40% higher blood oxygenation (Figure 6.5 b) in the transplanted 
left lung. The protein (Figure 6.5 c) and neutrophil content of the bronchoalveolar lavage 
fluid (Figure 6.5 d) and the neutrophil infiltration of the transplanted lung (Figure 6.5 e) were 
much lower in the AAT-treated lungs in comparison to the albumin-treated lungs after four 
hours of reperfusion. 
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Figure 6.5 Primary graft dysfunction is reduced by AAT. Left lungs of C57BL/6J donor 
mice were either stored in Perfadex supplemented with wild type AAT (AATwt) or albumin at 
4°C for 18 hours cold ischemia time. Four hours after orthotopic lung transplantation, 
C57BL/6J recipient mice were sacrificed and the outcome of the two treatment groups were 
compared (n=4-5 per group). (a) H&E staining depicting the tissue morphology of a 
transplanted left lung (scale bars: 200 µm). (b) pO2 (partial oxygen pressure) of the 
oxygenated blood in the left heart ventricle was determined after clamping the right bronchus 
for five minutes. During measurement of the oxygen exchange function only the transplanted 
left lung was mechanically ventilated. (c) Total protein concentration in the bronchoalveolar 
lavage fluid and (d) bronchoalveolar lavage neutrophil count for the two different treatment 
groups. (e) Immunohistochemistry (scale bars, 200 µm) and quantification of neutrophils in 
the transplanted left lungs from 10 randomly chosen visual microscopic fields. Data are 
represented as mean ± SEM and compared with a Mann-Whitney test (**p=0.0159, *p<0.05). 
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 Lung grafts are not preserved by a non-inhibitory AAT variant 6.2.5
To explore potential pleiotropic effects of AAT in graft protection, we separated the anti-
proteolytic functions of the RCL from other AAT-associated modulatory functions on the 
remaining surface of the molecule. We eliminated trypsin-, chymotrypsin- or elastase-
targeting specificity by substituting two residues in the RCL by aspartate residues (position 
P4 and P2) and two residues by a proline and serine residue (P3 and P1, respectively) 
(Figure 6.6 a). Changing the P4 Ala-355 and the P2 Pro-357 to a negatively charged Asp 
alters the hydrophobic nature of the RCL and reduces the interactions of AAT with 
phospholipid bilayers88. Shifting the Pro-357 to position 356 (P3) and replacing the 
methionine-358 conservatively by a serine alters the canonical inhibitory conformation and ß-
pleated strand extension of the RCL (P4 to P3’)89 and its specificity which are both required 
for the inhibition of serine proteases.  
In accordance with our assumptions, the RCL mutant of AAT (AATmt) produced in HEK 293 
cells72 was no longer able to inhibit murine and human neutrophil elastase (NE) and 
proteinase 3 (PR3) (Figure 6.6 b). However, the purified recombinant wild type AAT (AATwt) 
inhibited human and mouse NE and PR3 effectively. We intentionally designed the sequence 
modifications in the RCL of AAT to abolish cleavage by various mammalian proteases 
(assessed with the programs Prosper, Cascleave2.0 and PeptideCutter).  
In the lung transplantation experiments with AATmt in direct comparison to albumin, acute 
lung inflammation as judged from histology sections (Figure 6.6 c), the oxygenation of blood 
in the transplanted left lobe (Figure 6.6 d), and the protein content in the bronchoalveolar 
lavage fluid (Figure 6.6 e) was indistinguishable between the two treatment groups. Also the 
amount of infiltrating neutrophils in the BAL was not significantly different between the two 
treatment groups (Figure 6.6 f). 
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Figure 6.6 A reactive center loop variant of AAT (AATmt), unable to inhibit proteases, 
added to the preservation solution is ineffective. (a) Structure of the non-inhibitory 
reactive center loop variant (mutant AAT, AATmt) with replaced residues at P4 (A→D) and P2 
(P→D) and P1 (M→S) with a more polar residue and shifting the P2 proline to the P3 (I→P) 
position. The new design contains conserved hydrophobic intramolecular interactions in the 
extended loop, however, the conformation and flexibility of the loop was altered by the 
proline at P3. (b) Proteolytic activities of human (h) and murine (m) neutrophil elastase (NE) 
and proteinase 3 (PR3) with or without the addition of AATwt or AATmt. Data represent three 
independent experiments (n=3, ± SEM). (c to f) Left donor lungs from C57BL/6J mice were 
stored in either AATmt or albumin supplemented Perfadex at 4°C for 18 hours. Recipient mice 
(C57BL/6J) were sacrificed 4 h after transplantation (n=4-5 per group). (c) H&E staining 
illustrating the tissue morphology of a left lung after orthotopic transplantation (scale bars, 
200 μm). (d) pO2 (partial oxygen pressure) measured in blood collected from the left 
ventricles of the heart, five minutes after clamping the right bronchus. (e) Total protein 
concentration in the bronchoalveolar lavage fluid and (f) bronchoalveolar lavage neutrophil 
count. Data are represented as mean ± SEM. 
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 PR3 and NE double deficient mice exhibit enhanced primary graft function 6.2.6
To corroborate the detrimental impact of neutrophil serine proteases in PGD further, we 
compared wild type and PR3/NE double deficient mice as graft recipients. For these 
experiments we used donor mice with the same genetic background as the recipients 
(C57BL/6J). The alveoli structure of the transplanted lobe of the double knockout mice 
appeared much healthier than that of wild type mice after 4 hours of reperfusion as assessed 
by hematoxylin and eosin staining (Figure 6.7 a). After four hours of reperfusion the gas 
exchange function of the transplanted lobe was clearly preserved in PR3 and NE deficient 
mice. However, the lung graft in wild type recipient mice performed poorly (Figure 6.7 b). 
The mean partial oxygen pressure was 80% in the arterial blood of the left ventricle of 
knockout mice compared to only 50% in wild type recipient group after clamping the 
bronchus of the non-transplanted right lung. The degree of protein exudation (Figure 6.7 c) 
and cellular content of neutrophils in the bronchoalveolar lavage fluid (Figure 6.7 d) were not 
significantly different in the knockout group than in the wild type recipients. 
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Figure 6.7 Graft dysfunction is mainly triggered by neutrophil elastase and proteinase 
3. Donor lungs were taken from wild type mice (C57BL/6J) and perfused with and stored in 
Perfadex supplemented with albumin (1 mg/ml) for 18 hours at 4°C (cold ischemia). 
Afterwards, the lungs were orthotopically either transplanted into wild type C57BL/6J mice or 
into Ela2-/-Prtn3-/- deficient mice with the same genetic background. Mice were sacrificed after 
4 h of reperfusion (n=4-5 per group). (a) H&E staining illustrating the tissue morphology of a 
transplanted left lung (scale bars, 200 μm). (b) pO2 (partial oxygen pressure) measured in 
blood collected from the left ventricles of the heart, five minutes after clamping the right 
bronchus. (c) Protein concentration in bronchoalveolar lavage fluid and (d) bronchoalveolar 
lavage neutrophil count in the transplanted mice. Data are represented as mean ± SEM and 
compared with a Mann-Whitney test (*p<0.05). 
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 AAT in lung transplantation – Discussion 6.3
Donor lungs transported and stored for more than 6 hours are discarded by transplant 
surgeons because of an unacceptably high risk of graft dysfunctions. This short preservation 
time restricts the availability of donor lungs and limits the area of an organ sharing 
geographic region. Extended hypothermic ischemia times increase the extent of metabolic 
and structural changes in the transplant and, consequently, the intensity of the early innate 
immune response in the transplanted organ after the onset of reperfusion, and therefore the 
risk of PGD after transplantation. The greatest lung tissue damage is thought to be caused 
by the return of blood plasma and cellular blood components at 37°C after transplantation81. 
Intrigued by the multiple facets of AAT and as it is available for long term augmentation 
therapy in adults with emphysema due to severe AAT deficiency, we explored its clinical 
potential in organ conservation during cold ischemic storage and in graft protection from 
reperfusion injury after lung transplantation in a demanding, clinically relevant mouse model. 
We discussed that AAT in the preservation solution diffused into the perivascular and 
interstitial space throughout perfusion and storage of the transplant and was, therefore, 
optimally deposited in advance to protect the lung against the influx of adhering and 
extravasating neutrophils around the blood vessels. The anti-protease shield of AAT 
represented the most pivotal mechanism of lung preservation in this clinical setting. More 
precisely, our results indicate that the inhibition of neutrophil serine proteases, such as 
proteinase 3 and neutrophil elastase plays the most pivotal role in protecting the donor organ 
during reperfusion. 
However, several alternative mechanisms of tissue protection and AAT’s anti-inflammatory 
function unrelated to its anti-protease functions have been presented in several studies 90-97. 
To clarify the paramount therapeutic mechanism of AAT in lung graft protection during 
reperfusion, we separated the anti-proteolytic functions of the RCL from other potential 
functions of the AAT molecule. AAT primarily inhibits NE and PR3 and also other proteases 
like cathepsin G and trypsin-like enzymes, but to a much lesser extent21,98-101. Serine 
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proteases are active in an environment of neutral pH after regulated secretion or activation of 
zymogens. They occur in the oxidizing extra- and pericellular environment or within the 
secretory route including storage granules. Therefore, it was unlikely that these proteases 
were inhibited in the cytosol after membrane binding88, endocytosis102 and translocation into 
the cytosol103,104. Inhibition of caspases90,105, and calpain I 106 in the cytosol have been 
inferred to be responsible for additional anti-inflammatory properties of the wild type AAT106-
108. Our results strongly indicate that non-protease mediated functions of AAT do not 
significantly account for organ protection during the early phase of reperfusion after 
transplantation. 
In accordance with our results using the non-inhibitory AAT variant we found that PR3 and 
NE double deficient mice exhibited enhanced primary graft functions compared to wild type 
mice. The homologs of human PR3 and NE in the mouse are only expressed in the 
myelomonocyte lineage and constitutively deposited in the neutrophils’ primary granules100. 
Mice, deficient of these two proteases in the germline, do not exhibit any biological or 
developmental change in peripheral tissues and organs and no divergent phenotype can be 
detected under normal housing and living conditions25. Therefore, these mice were optimally 
suited to clarify the role of neutrophil serine proteases after initiating reperfusion of the lung 
graft. In summary, these findings in PR3/NE knockout mice were in agreement with recent 
observations in macaques after prolonged inhibition of cathepsin C, which resulted in the 
depletion of serine proteases in neutrophils109. The neutrophil migration and recruitment to 
the lungs and bronchi was not different in response to tracheal instillation of LPS with these 
experimental pharmacological conditions. 
The preservation technique in our preclinical study reflects very closely how grafts are 
handled in a routine thoracosurgical setting. The addition of AAT to Perfadex at a final 
concentration of 1 mg/ml is a safe and easily acceptable modification of the most frequently 
used preservation solution. This natural human plasma protein has already been approved 
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for long term substitution therapy in patients with constitutively low levels of AAT, who 
developed emphysema. 
When AAT does not have to compete with other plasma proteins endocytosis and 
transcytosis by the lung endothelium102,110 is expected to be more efficient than its uptake 
from whole blood, even when additional AAT is administered intravenously prior to 
transplantation surgery. Hence, flushing and perfusion with 15 µM (1 mg/ml) AAT in Perfadex 
solution is sufficient to deliver the inhibitor to endothelial cells and interstitial lung space after 
removal of the donor lung from a brain-dead donor. 
When a single dose of 60 µg/g AAT was intraperitoneally injected, the tissue levels of AAT in 
the murine lungs were clearly lower than in the transplanted AAT-perfused lungs after four 
hours. Ex vivo perfusion of the graft with AAT has a great benefit over its systemic delivery to 
the recipient, and in addition this procedure complies with existent ethical standards. With 
this protocol, we achieved maximum tissue levels of AAT in the transplanted tissue, before 
the first activated neutrophils reach it together with other soluble plasma components after 
the lungs are reconnected to the recipient’s circulation. 
Our experiments with an AAT RCL mutant and with PR3/NE deficient mice proved our 
hypothesis that the protease inhibiting functions of AAT on neutrophils in the early phase of 
blood reperfusion were most important and sufficient to guard the lung graft from immediate 
inflammatory damage after prolonged storage times. Possibly, other specific inhibitors of NE 
would be equally effective. Target specificity and very low toxicity of the utilized inhibitors, 
however, are crucial for drug safety. For instance, a previous clinical study with the inhibitor 
aprotinin to reduce PGD had to be canceled prematurely as renal toxicity of aprotinin was 
discerned111. 
In contrast, the organ conservation procedure presented in this thesis on the basis of an 
appropriately designed animal study, would be ethically acceptable, technically feasible in a 
clinical trial, well corroborated by long-standing research on AAT and its clinical application. 
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Moreover, the proposed protocol would be applicable to organ transplantation surgery in 
general. Improved graft protection by inhibiting PR3 and NE locally in the transplant, can be 
directly translated into clinical practice. It is expected to improve transplantation outcome and 
to help solve the organ shortage problem. The study we performed is a prerequisite for 
clinical trials to utilize AAT not only for diseased AAT-deficiency patients, but also for the 
preservation and protection of organ viability, especially after prolonged cold ischemia. 
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8. Abbreviations 
µl   Microliter 
aa   Amino acid 
AAT   α-1-antitrypsin proteinase inhibitor 
APS   Ammonium persulfate 
Asp   Aspartic acid 
BAL   Bronchoalveolar lavage 
BALF   Bronchoalveolar lavage fluid 
bp   Base pair 
Cat. No.  Catalog number 
CATG   Cathepsin G 
CHTR   Chymotrypsin 
Cys   Cysteine 
Da   Dalton 
ddH2O   Double destilled water  
DNA   Deoxyribonucleic acid 
ELISA   Enzyme-linked immunosorbent assay 
Endo H  Endo-ß-N-acetylglucosaminidase H 
FRET   Förster/Fluorescence resonance energy transfer 
HDL   High density lipoprotein 
HEK   Human embryonic kidney cell line 
His   Histidine 
HPL   Human platelet lysate 
HRP   Horseradish peroxidase 
i. p.   Intra peritoneal 
IPTG   Isopropyl β-D-1-thiogalactopyranoside 
KLK3   Kallikrein 3 
LDL   Low density lipoprotein 
mAb   Monoclonal antibody 
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min   Minutes 
mRNA   Messenger ribonucleic acid 
MS   Mass spectrometry 
NE   Neutrophil elastase 
NEB   New England Biolabs 
NSP4   Neutrophil serine protease 4 
OD   Optic density 
PBMC   Peripheral blood mononuclear cell 
PBS   Phosphate buffered saline 
PDB   Protein databasePEI   Polyethyleneimine 
PGD   Primary graft dysfunction 
pI   Isoelectric point 
PIPES   Piperazine-N,N’-bis(2-ethanesulfonic acid) 
PMN   Polymorphonuclear cells  
PNGase F  Peptide -N-Glycosidase F 
PR3   Proteinase 3 
PVDF   Polyvinylidene difluoride 
RCL   Reactive center loop 
RIPA   Radioimmunoprecipitation assay buffer 
rpm   Rounds per minute 
S2   Schneider 2 
SBzI   Thiobenzyl ester 
sec   Seconds 
Ser   Serine 
Serpin   Serine protease inhibitor 
Sulfo-NHS-Biotin Biotin 3-sulfo-N-hydroxycuccinimide ester sodium salt 
SUMO   Small ubiquitin-related modifier 
TCEP    Tris(2-carboxyethyl) phosphine 
TEMED  Tetramethylethylenediamine 
TR   Trypsin 
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9. Appendix 
 Vector Maps 9.1
 
 
Figure 9.1 Vector map of the pET-24(+) plasmid. Cloing of serpina2 into pET-24 was 
carried out by digesting the vector with the restriction enzymes BamHI and XhoI to express 
serpina2 in E. coli cell lines. The vector carries a gene for kanamycin resistance. 
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Figure 9.2 Vector map of the pTT5 plasmid. This vector was used to express different 
serpins in HEK 293 cells. The important features of this vector are an E. coli (pMB1ori) and 
EBV (OriP) specific origin of replication, a promotor of the cytomegalovirus (CMV), an 
adenovirus tripartite leader (TPL), a major late promotor (MLP), a rabbit bet-globin 
polyadenylation signal (pA) and an ampicillin resistance gene. 
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 Screeing for serpina2 specific antibodies 9.2
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Oliver Eickelberg, Dieter E. Jenne. 
‘Preservation with alpha-1-antitrypsin improves primary graft function of murine lung 
transplants’ 
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Jessica Götzfried, Susana Seixas, Artur Mayerhofer, Matthias Trottmann, Christoph Meyer, 
Agnese Petrera, Stefanie M. Hauck, Herbert Schiller, Elisabeth Kremmer, Dieter E. Jenne. 
‚More than just a pseudogene: serpina2 is an epididymis specific protease inhibitor’ 
(manuscript in preparation) 
 
Parts of this thesis have been published: 
Malik R, Dau T, Gonik M, Sivakumar A, Deredge DJ, Edeleva EV, Götzfried J, van der Laan 
SW, Pasterkamp G, Beaufort N, Seixas S, Bevan S, Lincz LF, Holliday EG, Burgess AI, 
Rannikmäe K, Minnerup J, Kriebel J, Waldenberger M, Müller-Nurasyid M, Lichtner P, 
Saleheen D; International Stroke Genetics Consortium., Rothwell PM, Levi C, Attia J, Sudlow 
CL, Braun D, Markus HS, Wintrode PL, Berger K, Jenne DE, Dichgans M., 2017.  
Common coding variant in SERPINA1 increases the risk for large artery stroke.  
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‘Tissue distribution and function of the putative serine protease inhibitor serpina2 and its 
modifying impact on lung diseases’, 32nd Winter School on Proteinases and Their Inhibitors. 
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‘Storage and Transplantability of Donor Lungs is extended by Alpha-1-Antitrypsin as an 
Additive to Perfadex’, 34nd Winter School on Proteinases and Their Inhibitors. Italy, 2017 
(Best presentation award) 
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‘More than just a pseudogene: SERPINA2 is an epididymis specific protease inhibitor’, 
Gordon Research Conference: Proteolytic Enzymes an Their Inhibitors. Italy, 2016 
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